DiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth Care
Hypoglycemic AgentsSulfonylurea CompoundsChlorpropamideGlipizideDiabetes Mellitus, Type 2Diabetic DietIsoindolesGliclazideMetforminBlood GlucoseDiabetes MellitusHemoglobin A, GlycosylatedGlyburideCyclohexanesPhenforminDipeptidyl-Peptidase IV InhibitorsInsulinHypoglycemiaCarbamatesAdministration, OralTolbutamideThiazolidinedionesDiabetes ComplicationsInsulin, Long-ActingC-PeptideDiabetes Mellitus, Type 1PhytotherapyDiabetic AngiopathiesInsulin ResistanceRetrospective StudiesDrug Therapy, CombinationGlucoseTreatment OutcomeBody WeightBody Mass IndexRisk FactorsCross-Sectional StudiesPatents as TopicHyperglycemiaInventionsIntellectual PropertyMedlinePlusGross Domestic ProductInternetBiological ProductsSoftwareUser-Computer InterfaceKidney DiseasesRenal Insufficiency, ChronicKidney Failure, ChronicPeriodicals as TopicBiphasic InsulinsInsulins
Hypoglycemic Agents
Substances which lower blood glucose levels.
Sulfonylurea Compounds
Chlorpropamide
A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)
Glipizide
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Diabetic Diet
A diet prescribed in the treatment of diabetes mellitus, usually limited in the amount of sugar or readily available carbohydrate. (Dorland, 27th ed)
Isoindoles
Benzopyrroles with the nitrogen at the number two carbon, in contrast to INDOLES which have the nitrogen adjacent to the six-membered ring.
Gliclazide
An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Metformin
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Blood Glucose
Glucose in blood.
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Hemoglobin A, Glycosylated
Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.
Glyburide
An antidiabetic sulfonylurea derivative with actions similar to those of chlorpropamide.
Cyclohexanes
Six-carbon alicyclic hydrocarbons.
Phenformin
A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
Insulin
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
Carbamates
Derivatives of carbamic acid, H2NC(=O)OH. Included under this heading are N-substituted and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes, and polymers that include repeating units of carbamate are referred to as POLYURETHANES. Note however that polyurethanes are derived from the polymerization of ISOCYANATES and the singular term URETHANE refers to the ethyl ester of carbamic acid.
Administration, Oral
The giving of drugs, chemicals, or other substances by mouth.
Tolbutamide
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Thiazolidinediones
THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).
Diabetes Complications
Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE.
Insulin, Long-Acting
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
C-Peptide
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
Phytotherapy
Use of plants or herbs to treat diseases or to alleviate pain.
Diabetic Angiopathies
VASCULAR DISEASES that are associated with DIABETES MELLITUS.
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
Retrospective Studies
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Drug Therapy, Combination
Therapy with two or more separate preparations given for a combined effect.
Glucose
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
Treatment Outcome
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Body Mass Index
An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)
Risk Factors
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Cross-Sectional Studies
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
Patents as Topic
Exclusive legal rights or privileges applied to inventions, plants, etc.
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.
Inventions
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
Intellectual Property
Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)
MedlinePlus
NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.
Gross Domestic Product
Value of all final goods and services produced in a country in one year.
Internet
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Biological Products
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Software
Sequential operating programs and data which instruct the functioning of a digital computer.
User-Computer Interface
The portion of an interactive computer program that issues messages to and receives commands from a user.
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Periodicals as Topic
A publication issued at stated, more or less regular, intervals.
Biphasic Insulins
An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.
Insulins
Peptide hormones that cause an increase in the absorption of GLUCOSE by cells within organs such as LIVER, MUSCLE and ADIPOSE TISSUE. During normal metabolism insulins are produced by the PANCREATIC BETA CELLS in response to increased GLUCOSE. Natural and chemically-modified forms of insulin are also used in the treatment of GLUCOSE METABOLISM DISORDERS such as DIABETES MELLITUS.

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. (1/7377)

OBJECTIVE: To determine whether metformin. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after metformin therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more hirsute (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to metformin. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation.  (+info)

Enantioselective inhibition of the biotransformation and pharmacological actions of isoidide dinitrate by diphenyleneiodonium sulphate. (2/7377)

1. We have shown previously that the D- and L- enantiomers of isoidide dinitrate (D-IIDN and L-IIDN) exhibit a potency difference for relaxation and cyclic GMP accumulation in isolated rat aorta and that this is related to preferential biotransformation of the more potent enantiomer (D-IIDN). The objective of the current study was to examine the effect of the flavoprotein inhibitor, diphenyleneiodonium sulphate (DPI), on the enantioselectivity of IIDN action. 2. In isolated rat aortic strip preparations, exposure to 0.3 microM DPI resulted in a 3.6 fold increase in the EC50 value for D-IIDN-induced relaxation, but had no effect on L-IIDN-induced relaxation. 3. Incubation of aortic strips with 2 microM D- or L-IIDN for 5 min resulted in significantly more D-isoidide mononitrate formed (5.0 +/- 1.5 pmol mg protein(-1)) than L-isoidide mononitrate (2.1 +/- 0.7 pmol mg protein(-1)) and this difference was abolished by pretreatment of tissues with 0.3 microM DPI. DPI had no effect on glutathione S-transferase (GST) activity or GSH-dependent biotransformation of D- or L-IIDN in the 105,000 x g supernatant fraction of rat aorta. 4. Consistent with both the relaxation and biotransformation data, treatment of tissues with 0.3 microM DPI significantly inhibited D-IIDN-induced cyclic GMP accumulation, but had no effect on L-IIDN-induced cyclic GMP accumulation. 5. In the intact animal, 2 mg kg(-1) DPI significantly inhibited the pharmacokinetic and haemodynamic properties of D-IIDN, but had no effect L-IIDN. 6. These data suggest that the basis for the potency difference for relaxation by the two enantiomers is preferential biotransformation of D-IIDN to NO, by an enzyme that is inhibited by DPI. Given that DPI binds to and inhibits NADPH-cytochrome P450 reductase, the data are consistent with a role for the cytochromes P450-NADPH-cytochrome P450 reductase system in this enantioselective biotransformation process.  (+info)

Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin. (3/7377)

1. Proliferative effects of CCK peptides have been examined in rat anterior pituitary GH3 cells, which express CCK2 receptors. 2. CCK-8s, gastrin(1-17) and its glycine-extended precursor G(1-17)-Gly, previously reported to cause proliferation via putative novel sites on AR4-2J and Swiss 3T3 cells, elicited significant dose dependent increases of similar magnitude in [3H]thymidine incorporation over 3 days in serum-free medium of 39 +/- 10% (P < 0.01, n = 20), 37 +/- 8% (P < 0.01, n = 27) and 41 +/- 6% (P < 0.01, n = 36) respectively. 3. CCK-8s and gastrin potentially stimulated mitogenesis (EC50 values 0.12 nM and 3.0 nM respectively), whilst G-Gly displayed similar efficacy but markedly lower potency. L-365,260 consistently blocked each peptide. The CCK2 receptor affinity of G-Gly in GH3 cells was 1.09 microM (1.01;1.17, n = 6) and 5.53 microM (3.71;5.99, n = 4) in guinea-pig cortex. 4. 1 microM G-Gly weakly stimulated Ca2+ increase, eliciting a 104 +/- 21% increase over basal Ca2+ levels, and was blocked by 1 microM L-365,260 whilst CCK-8s (100 nM) produced a much larger Ca2+ response (331 +/- 14%). 5. Insulin dose dependently enhanced proliferative effects of CCK-8s with a maximal leftwards shift of the CCK-8s curve at 100 ng ml(-1) (17 nM) (EC50 decreased 500 fold, from 0.1 nM to 0.2 pM; P < 0.0001). 10 microg ml(-1) insulin was supramaximal reducing the EC50 to 5 pM (P = 0.027) whilst 1 ng ml(-1) insulin was ineffective. Insulin weakly displaced [125I]BHCCK binding to GH3 CCK2 receptors (IC50 3.6 microM). 6. Results are consistent with mediation of G-Gly effects via CCK2 receptors in GH3 cells and reinforce the role of CCK2 receptors in control of cell growth. Effects of insulin in enhancing CCK proliferative potency may suggest that CCK2 and insulin receptors converge on common intracellular targets and indicates that mitogenic stimuli are influenced by the combination of extracellular factors present.  (+info)

Studies of the role of endothelium-dependent nitric oxide release in the sustained vasodilator effects of corticotrophin releasing factor and sauvagine. (4/7377)

1. The mechanisms of the sustained vasodilator actions of corticotrophin-releasing factor (CRF) and sauvagine (SVG) were studied using rings of endothelium de-nuded rat thoracic aorta (RTA) and the isolated perfused rat superior mesenteric arterial vasculature (SMA). 2. SVG was approximately 50 fold more potent than CRF on RTA (EC40: 0.9 +/- 0.2 and 44 +/- 9 nM respectively, P < 0.05), and approximately 10 fold more active in the perfused SMA (ED40: 0.05 +/- 0.02 and 0.6 +/- 0.1 nmol respectively, P < 0.05). Single bolus injections of CRF (100 pmol) or SVG (15 pmol) in the perfused SMA caused reductions in perfusion pressure of 23 +/- 1 and 24 +/- 2% that lasted more than 20 min. 3. Removal of the endothelium in the perfused SMA with deoxycholic acid attenuated the vasodilatation and revealed two phases to the response; a short lasting direct action, and a sustained phase which was fully inhibited. 4. Inhibition of nitric oxide synthase with L-NAME (100 microM) L-NMMA (100 microM) or 2-ethyl-2-thiopseudourea (ETPU, 100 microM) had similar effects on the vasodilator responses to CRF as removal of the endothelium, suggesting a pivotal role for nitric oxide. However the selective guanylate cyclase inhibitor 1H-[l,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ, 10 microM) did not affect the response to CRF. 5. High potassium (60 mM) completely inhibited the vasodilator response to CRF in the perfused SMA, indicating a role for K channels in this response. 6. Compared to other vasodilator agents acting via the release of NO, the actions of CRF and SVG are strikingly long-lasting, suggesting a novel mechanism of prolonged activation of nitric oxide synthase.  (+info)

Acute troglitazone action in isolated perfused rat liver. (5/7377)

1. The thiazolidinedione compound, troglitazone, enhances insulin action and reduces plasma glucose concentrations when administered chronically to type 2 diabetic patients. 2. To analyse to what extent thiazolidinediones interfere with liver function, we examined the acute actions of troglitazone (0.61 and 3.15 microM) on hepatic glucose and lactate fluxes, bile secretion, and portal pressure under basal, insulin- and/or glucagon-stimulated conditions in isolated perfused rat livers. 3. During BSA-free perfusion, high dose troglitazone increased basal (P < 0.01), but inhibited glucagon-stimulated incremental glucose production by approximately 75% (10.0 +/- 2.5 vs control: 40.0 +/- 7.2 micromol g liver(-1), P < 0.01). In parallel, incremental lactate release rose approximately 6 fold (13.1 +/- 5.9 vs control: 2.2 +/- 0.8 mmol g liver(-1), P < 0.05), while bile secretion declined by approximately 67% [0.23 +/- 0.02 vs control: 0.70 +/- 0.05 mg g liver(-1) min(-1)), P < 0.001]. Low dose troglitazone infusion did not enhance the inhibitory effect of insulin on glucagon-stimulated glucose production, but rapidly increased lactate release (P < 0.0005) and portal venous pressure (+0.17 +/- 0.07 vs +0.54 +/- 0.07 cm buffer height, P < 0.0001). 4. These results indicate that troglitazone exerts both insulin-like and non-insulin-like hepatic effects, which are blunted by addition of albumin, possibly due to troglitazone binding.  (+info)

Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats. (6/7377)

To examine the role of changes in myocardial metabolism in cardiac dysfunction in diabetes mellitus, rats were injected with streptozotocin (65 mg/kg body wt) to induce diabetes and were treated 2 wk later with the carnitine palmitoyltransferase inhibitor (carnitine palmitoyltransferase I) etomoxir (8 mg/kg body wt) for 4 wk. Untreated diabetic rats exhibited a reduction in heart rate, left ventricular systolic pressure, and positive and negative rate of pressure development and an increase in end-diastolic pressure. The sarcolemmal Na+-K+-ATPase activity was depressed and was associated with a decrease in maximal density of binding sites (Bmax) value for high-affinity sites for [3H]ouabain, whereas Bmax for low-affinity sites was unaffected. Treatment of diabetic animals with etomoxir partially reversed the depressed cardiac function with the exception of heart rate. The high serum triglyceride and free fatty acid levels were reduced, whereas the levels of glucose, insulin, and 3,3',-5-triiodo-L-thyronine were not affected by etomoxir in diabetic animals. The activity of Na+-K+-ATPase expressed per gram heart weight, but not per milligram sarcolemmal protein, was increased by etomoxir in diabetic animals. Furthermore, Bmax (per g heart wt) for both low-affinity and high-affinity binding sites in control and diabetic animals was increased by etomoxir treatment. Etomoxir treatment also increased the depressed left ventricular weight of diabetic rats and appeared to increase the density of the sarcolemma and transverse tubular system to normalize Na+-K+-ATPase activity. Therefore, a shift in myocardial substrate utilization may represent an important signal for improving the depressed cardiac function and Na+-K+-ATPase activity in diabetic rat hearts with impaired glucose utilization.  (+info)

Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. (7/7377)

Previous results from our laboratory have suggested that morphine can attenuate neutrophil activation in patients with acute myocardial infarction. To elucidate if morphine preconditioning (PC) has the same effects via activation of neutrophil endopeptidase 24.11 (NEP), we measured serum levels of intercellular adhesion molecule-1 (ICAM-1), gp100MEL14 and NEP in adult Wistar rats subjected to ten different protocols (n = 10 for each) at baseline, immediately after and 2 h after morphine PC. All groups were subjected to 30 min of occlusion and 2 h of reperfusion. Similarly, morphine-induced PC was elicited by 3-min drug infusions (100 micrograms/kg) interspersed with 5-min drug-free periods before the prolonged 30-min occlusion. Infarct size (IS), as a percentage of the area at risk (AAR), was determined by triphenyltetrazolium staining. Pretreatment with morphine increased NEP activities (9.86 +/- 1.98 vs. 5.12 +/- 1.10 nmol/mg protein in control group; p < 0.001). Naloxone (mu-opioid receptor antagonist) (4.82 +/- 1.02 nmol/mg protein) and phosphoramidon (NEP inhibitor) (4.66 +/- 1.00 nmol/mg protein) inhibited morphine-activated NEP, whereas glibenclamide (ATP-sensitive potassium channel antagonist) and chelerythrine (protein kinase C inhibitor) had no effects. The ICAM-1 and gp100MEL14 of the third sampling were lowest for those with morphine PC (280 +/- 30 ng/ml and 2.2 +/- 0.7 micrograms/ml; p < 0.001), but naloxone (372 +/- 38 ng/ml and 3.8 +/- 0.9 micrograms/ml) and phosphoramidon (382 +/- 40 ng/ml and 4.2 +/- 1.1 micrograms/ml) abolished the above phenomenon. IS/AAR were definitely lowest for those with morphine PC (24 +/- 7%; p < 0.05). Morphine preconditioning increases NEP activities to attenuate shedding of gp100MEL14 and to ICAM-1 and, thus, provides myocardial protection.  (+info)

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). (8/7377)

Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.  (+info)

Combinations of insulin and oral glucose-lowering drugs for people with type 2 diabetes on insulin treatment | CochraneCombinations of insulin and oral glucose-lowering drugs for people with type 2 diabetes on insulin treatment | Cochrane
Introduction Many guidelines on type 2 diabetes recommend a glycosylated haemoglobin A1c (HbA1c) level below 7%. HbA1c levels in the blood express glucose or glycaemic control over a longer time period (two to three months). During the course of type 2 diabetes it will get more difficult to reach these levels with lifestyle modification (diet, exercise or both) and oral glucose-lowering agents alone. Finally, a substantial number of people will need insulin therapy for better glycaemic control. Insulin therapy can be initiated as insulin alone, called monotherapy (which means that oral glucose-lowering medication will be stopped) or in combination with oral glucose-lowering agents. In the former case, oral blood glucose-lowering agents can be added at a later stage, if insulin monotherapy fails to achieve a good HbA1c level. Hypoglycaemia and weight gain are the most common and well known side effects of insulin therapy. Adding oral agents to insulin could reduce the required insulin dose and ...
https://www.cochrane.org/CD006992/ENDOC_combinations-insulin-and-oral-glucose-lowering-drugs-people-type-2-diabetes-insulin-treatment
Oral Anti-Diabetic Drug Market In-Depth Analysis, Growing Health Benefits, Drivers & Latest Business Opportunities From 2020 |...Oral Anti-Diabetic Drug Market In-Depth Analysis, Growing Health Benefits, Drivers & Latest Business Opportunities From 2020 |...
Anti-diabetic Drug refers to the medications consumed orally that are prescribed to treat diabetes mellitus (type 2). It treats diabetes (type 2) by lowering down the blood sugar level. These are also known as oral hypoglycaemic agentsororal antihyperglycemic agents. Oral anti-diabetic drugs are often prescribed as monotherapy but in severe cases, can be given in combination with insulin. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Oral Anti-Diabetic Drug Report by Material, Application, and Geography - Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).. In this report, the global Oral Anti-Diabetic Drug market is valued at USD XX million in 2020 and is projected to reach USD ...
http://www.vadodaranewsflash.com/story/100478/oral-antidiabetic-drug-market-indepth-analysis-growing-health-benefits-drivers-latest-business-opportunities-from-2020-pfizer-takeda-sanofi-and-novartis-radiant-insights-inc.html
Plants with Anti-Diabetes Mellitus PropertiesPlants with Anti-Diabetes Mellitus Properties
The incidence and severity of diabetes mellitus is increasing worldwide, presenting a significant burden to society both in economic terms and overall well-being. Fortunately, time-tested anti-diabetes mellitus plant foods exist that are safe and could be effective in addressing this condition when consumed judiciously with a concomitant change in lifestyle.. Plants with Anti-Diabetes Mellitus Properties presents an exhaustive compilation of the anti-diabetes mellitus activities of more than 1000 plants occurring worldwide. The author provides a brief botanical description, distribution, pharmacological properties, and phytochemicals, where appropriate. A list of traditional medicinal plants used to treat diabetes, but not tested for anti-diabetic activity, is also given.. This unique reference highlights anti-diabetes mellitus plant foods along with a list of the edible parts of plants with anti-diabetes mellitus properties. Anti-diabetes mellitus nutraceuticals are described with guidelines ...
http://basicebooks.net/plants-with-anti-diabetes-mellitus-properties
Oral Hypoglycemic Agents Mechanism Of Action - Website of cumaslag!Oral Hypoglycemic Agents Mechanism Of Action - Website of cumaslag!
Introduction Oral Agents General Considerations Oral Hypoglycemic Agents (OHAs) Oral Hyperglycemic Agents (AHAs) Sulfonylureas Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients. Reinhard G. Bretzel, MD, PHD, 1 Michael Eckhard, MD, 1 Wolfgang Landgraf, PHD, 2 David R. Owens, MD, FRCP, 3 and Thomas Linn, MD, PHD 1 1 Oral Hypoglycemic Agents Clinical Pearls for Washington Rx Therapeutic Interchange Program (TIP) Jennifer Oh, PharmD Pharmacy Practice Resident An oral hypoglycemic agent is a medication (usually a pill or capsule) that can be take by mouth to lower a high blood sugar toward normal. Prandin is one of six types of diabetes pills currently available to treat type 2 diabetes. Diabetes Mellitus (DM) is a chronic disease that is growing in prevalence worldwide ...
https://cumaslag.jimdo.com/2012/10/18/oral-hypoglycemic-agents-mechanism-of-action/
Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes - Full Text View -...Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes - Full Text View -...
This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant and the oral hypoglycemic drugs or MSC transplant and insulins or MSC transplant and the combination of the oral hypoglycemic drugs and insulins (experimental group) or the oral hypoglycemic drugs or insulins or the combination of the oral hypoglycemic drugs and insulins (control group). Patients will undergo MSC transplant at the start of the study on Day 0 and take the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. As control, some patients take the oral hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. At the same time, the dose of the oral hypoglycemic drugs and insulins should be regulated according to the level of blood sugar. After 3 months, patients will receive the second MSC transplantation. After six and twelve months from the first transplantation, patients will be ...
https://clinicaltrials.gov/ct2/show/NCT01413035?term=type+2+diabetes&recr=Open&rank=20
Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe...Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe...
OBJECTIVE-To evaluate whether treatment with insulin is advantageous compared with oral antidiabetes agents in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.. RESEARCH DESIGN AND METHODS-Newly diagnosed type 2 diabetic patients with severe hyperglycemia were hospitalized and treated with intensive insulin injections for 10-14 days. The oral glucose tolerance test (OGTT) was performed after intensive insulin treatment. After discharge, the patients were randomized to receive either insulin injections or oral antidiabetes drugs (OADs) for further management. The OGTT was repeated 6 months later, and β-cell function and insulin sensitivity were evaluated again. These subjects were continually followed up for another 6 months to evaluate their long-term glycemic control.. RESULTS-At the 6th month of the study, the A1C level was significantly lower in the insulin group than in the OAD group (6.33 ± 0.70% vs. 7.50 ± 1.50%; P = 0.002). During ...
https://care.diabetesjournals.org/content/31/10/1927.abstract
Initial Oral Glucose-Lowering Medications: Comparing Classes, Effectiveness - MPRInitial Oral Glucose-Lowering Medications: Comparing Classes, Effectiveness - MPR
While the American Diabetes Association and the American College of Physicians recommend metformin as the initial pharmacologic agent for glucose-lowering therapy in type 2 diabetes, long-term data comparing metformin to newer classes of glucose-lowering medications is limited.
http://www.empr.com/medical-news/initial-oral-glucose-lowering-medications-comparing-classes-effectiveness/article/379756/
Global and China Oral hypoglycemic agents and insulin analogues Industry Professional Market Report 2017 : ReportsnReportsGlobal and China Oral hypoglycemic agents and insulin analogues Industry Professional Market Report 2017 : ReportsnReports
[132 Pages Report] Check for Discount on Global and China Oral hypoglycemic agents and insulin analogues Industry Professional Market Report 2017 report by QYResearch Group. This report splits Oral hypoglycemic agents and insulin analogues market...
http://www.reportsnreports.com/reports/1147888-global-and-china-oral-hypoglycemic-agents-and-insulin-analogues-industry-professional-market-report-2017.html
Why a Diabetes Drug Could Help in Parkinsons DiseaseWhy a Diabetes Drug Could Help in Parkinsons Disease
When studying cells from a patient suffering from Parkinsons disease we saw that they lack an important protein which regulates the energy production, explains Fitzgerald. As a result, the cells keep on producing energy in their mitochondria-the cells powerhouses-unchecked and less regulated.. Energy production comes at the cost of the generation of free oxygen radicals. The radicals damage the cell and lead to aging and, in the long term, sometimes to cell death. The diabetes drug acts like a brake in this process. It slows down the uncontrolled generation of energy, thereby protecting the cells from the negative effects, the researcher reports.. The study by the Tübingen neuroscientists provides another indication that diabetes drugs might have a positive influence on certain types of Parkinsons disease. Only recently, an Anglo-American research collaboration showed that another diabetes drug can reduce movement disorder symptoms in patients with Parkinsons disease, says ...
http://www.innovations-report.com/html/reports/life-sciences/why-a-diabetes-drug-could-help-in-parkinson-s-disease.html
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2...How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2...
This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics.. The main study will last 32 weeks. However, all participants completing 32 weeks will be invited to continue for another 24 weeks taking the insulin and oral medication and exenatide treatment. This extension comparing insulin and oral medication with insulin and oral medication and exenatide will look at the long term weight loss/gain and blood sugar level control effects of this new drug regimen.. There is also a sub-study in the Clinical Research Center (CRC), which requires two 38-hour inpatient stays during the main study. This study offers the opportunity to study 24-hour blood sugar and metabolic patterns quantitatively. ...
https://clinicaltrials.gov/ct2/show/record/NCT00667732?term=%22Type+2+Diabetes%22&lup_s=01%2F28%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
Cardiovascular outcome trials of glucose-lowering medications: an update - published online 03/01/2019 - DiabetologiaCardiovascular outcome trials of glucose-lowering medications: an update - published online 03/01/2019 - Diabetologia
Philip Home. Cardiovascular outcome trials (CVOTs) of glucose-lowering medications that have been completed in recent years have provided welcome pointers towards best use of these drugs in diabetes care. However, many questions and uncertainties remained. In this issue, Philip Home (https://doi.org/10.1007/s00125-018-4801-1) discusses studies in three major glucose-lowering drug classes, which were published and presented recently (October/November 2018). These studies help to confirm or clarify our understanding of how the three classes should be positioned clinically and whether there are within-class differences. For dipeptidyl peptidase-4 (DPP4) inhibitors, CARMELINA confirmed neutrality for cardiovascular outcomes, with no heart failure signal, albeit in a highly selected population. For GLP-1 receptor agonists, the Harmony Outcome study confirmed an early and continuing benefit for cardiovascular protection for this class, independent of glucose- or body-weight-lowering. For ...
https://diabetologia-journal.org/editors-choice/cardiovascular-outcome-trials-of-glucose-lowering-medications-an-update/
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugsHospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
Colhoun , H M , Livingstone , S J , Looker , H C , Morris , A D , Wild , S H , Lindsay , R S , Reed , C , Donnan , P T , Guthrie , B , Leese , G P , McKnight , J , Pearson , D W M , Pearson , E , Petrie , J R , Philip , S , Sattar , N , Sullivan , F M , McKeigue , P & on behalf of the Scottish Diabetes Research Network Epidemiology Group 2012 , Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs Diabetologia , vol 55 , no. 11 , pp. 2929-2937 . DOI: 10.1007/s00125-012-2668- ...
http://aura.abdn.ac.uk/handle/2164/5619
Oral Anti-diabetes Drugs Market Key Vendors, Regional Analysis, Key Players and Competitive Landscape Forecasts by 2027|Sanofi,...Oral Anti-diabetes Drugs Market Key Vendors, Regional Analysis, Key Players and Competitive Landscape Forecasts by 2027|Sanofi,...
LOS ANGELES, United States: QY Research offers an overarching research and analysis-based study on, Global Oral Anti-diabetes Drugs Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global Oral Anti-diabetes Drugs market. The report is amalgamated depending on research procured from primary and secondary information. The global Oral Anti-diabetes Drugs market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Oral Anti-diabetes Drugs market. Players can use the ...
https://beveragemanager.net/uncategorized/13131/oral-anti-diabetes-drugs-market-key-vendors-regional-analysis-key-players-and-competitive-landscape-forecasts-by-2027sanofi-eli-lilly-astrazeneca-plc-astellas-pharma-inc/
The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients | Pakistan Journal of...The effect of short-term intensive insulin therapy in newly-diagnosed Type-2 diabetic patients | Pakistan Journal of...
Objectives: We aimed to determine the effect of short-term intensive insulin therapy (SIIT) on long-term glycemic control in newly-diagnosed Type-2 diabetes mellitus (nT2DM) patients.. Methods: In this retrospectively study conducted at Sakarya University Medical Faculty Training and Research Hospital Outpatient Clinic between 2016 and 2019, 65 nT2DM patients were enrolled soon after their SIIT was initiated and were followed for at least a year. Intensive insulin treatment was discontinued after three or 12 months in a total of 65 (23-73-year-old) patients who had been newly diagnosed with T2DM. Intensive insulin therapy was discontinued when glycemic control and the target Glycated Hemoglobin (HbA1c) level had been attained, after which oral anti-diabetic drug (OAD), long-term insulin, and diet therapies were pursued.. Results: There was a significant decrease in mean HbA1c from 11.25±1.96% to 6.67±1.07%. Fasting plasma glucose (FPG) was found to be an independent predictor of whether ...
http://pjms.org.pk/index.php/pjms/article/view/4013
Study finds Onglyza effective as Januvia in treating Type 2 diabetes - Drug Store NewsStudy finds Onglyza effective as Januvia in treating Type 2 diabetes - Drug Store News
Results from an 18-week phase 3 study in adults with Type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with Onglyza (saxagliptin) 5 mg per day was equally effective to the addition of treatment with Januvia (sitagliptin) 100 mg per day in reducing hemoglobin levels in patients.. This study was submitted to the European Medicines Agency as part of the marketing authorization application for Onglyza. Complete findings from this study will be submitted for publication in the first half of 2010.. Onglyza was approved by the Food and Drug Administration in late July.. We are pleased with the findings from this study, which support that the addition of ONGLYZA to metformin lowers HbA1c in adults with inadequate glycemic control despite treatment with metformin, said Andre Scheen, MD, Head of the Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Academic Hospital, Liege, Belgium.. Onglyza is a drug ...
http://migratedev.drugstorenews.com/article/study-finds-onglyza-effective-januvia-treating-type-2-diabetes/
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications | MetaDrug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications | Meta
There is a growing epidemic of type 2 diabetes (T2DM), and it is associated with various comorbidities. Patients with T2DM are usually treated with multiple drugs, and are therefore at an increased risk of harmful drug-drug interactions (DDIs). Several potentially life-threatening DDIs concerning oral antidiabetic drugs have been identified. This has mostly been initiated by case reports but, more recently, the understanding of their mechanisms has greatly increased. In this article, we review the pharmacokinetic DDIs concerning oral antidiabetics, including metformin, sulfonylureas, meglitinide analogs, thiazolidinediones and dipeptidyl peptidase-4 inhibitors, and the underlying mechanistic basis that can help to predict and prevent DDIs. In particular, the roles of membrane transporters and cytochrome P450 (CYP) enzymes in these DDIs are discussed. ...
https://www.meta.org/papers/drug-interactions-with-oral-antidiabetic-agents/22475684
FDA To Discuss The Diabetes Drug Standard In Two Day MeetingFDA To Discuss The Diabetes Drug Standard In Two Day Meeting
A prominent medical expert, Cardiologist Steven Nissen of the Cleveland Clinic urged the U.S. Food and Drug Administration to raise its standards for approving diabetes drugs on Tuesday. Nissen said that companies need to prove new drugs dont increase cardiovascular disease, the leading killer of diabetics. Nissen suggested that, in addition to requiring more pre-approval studies, companies should have large, long-term studies in place when a drug is approved to monitor whether the drug increases the risk of cardiovascular disease. He discussed the issue of diabetes drugs standards as a part of a two-day meeting starting Tuesday.
https://diabetes.taragana.net/fda-to-discuss-the-diabetes-drug-standard-in-two-day-meeting/
Repaglinide - DrugBankRepaglinide - DrugBank
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the
https://www.drugbank.ca/drugs/DB00912
Diabetes Drug Could Help Fight Cancer | Chemistry And PhysicsDiabetes Drug Could Help Fight Cancer | Chemistry And Physics
Could a long used diabetes drug be repurposed for cancer treatment? Researchers at Rice University have found a potential way to use the diabetes drug clas | Chemistry And Physics
https://www.labroots.com/trending/chemistry-and-physics/4696/diabetes-drug-help-fight-cancer
Mechanisms of Vasorelaxation Induced by Troglitazone, a Novel Antidiabetic Drug, in the Porcine Coronary Artery | CirculationMechanisms of Vasorelaxation Induced by Troglitazone, a Novel Antidiabetic Drug, in the Porcine Coronary Artery | Circulation
We found that a novel antidiabetic drug, TRO, relaxed the medial strips of the porcine coronary artery by decreasing [Ca2+]i and by shifting the [Ca2+]i-force relation to the right in smooth muscle. The rightward shift of [Ca2+]i-force relation indicated the decrease in Ca2+ sensitivity of the contractile apparatus as a whole. The decrease in [Ca2+]i was mainly caused by an inhibition of Ca2+ influx and partly caused by an inhibition of agonist/receptor-mediated Ca2+ release. TRO completely inhibited [Ca2+]i increase and Mn2+ influx induced by 100 nmol/L U46619, but only partially inhibited those induced by 30 mmol/L K+, although these two stimulations induced similar [Ca2+]i elevation and Mn2+ influx. This finding suggested that there was a difference in efficacy of TRO in inhibiting Ca2+ influx between stimulation with U46619 and K+ depolarization. On the other hand, although 60 mmol/L K+ induced similar force development to that obtained with 100 nmol/L U46619, TRO inhibited U46619-activated ...
http://circ.ahajournals.org/content/98/22/2446
Novel diabetes drugs sensitize cancer cells to chemotherapy agents | Science CodexNovel diabetes drugs sensitize cancer cells to chemotherapy agents | Science Codex
Scientists at Dana-Farber Cancer Institute have shown that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents, and they say such combinations should be explored to potentially improve outcomes for cancer patients.. Reporting in the Proceedings of the National Academy of Sciences, investigators demonstrated in cancer cell lines and animal models that the research compounds - similar to common anti-diabetic agents known as thiazolidinediones (TZDs) - sensitized lung tumor cells to carboplatin chemotherapy. Tumors in rodents treated with the combination of carboplatin and one of the experimental compounds, SR1664, weighed less than those in animals treated with carboplatin alone.. The research also showed that the combination sensitized triple-negative breast cancer cells in the laboratory, causing them to self-destruct. However, not all types of cancer cells appear to be made vulnerable to chemotherapy combined with the experimental compounds, the ...
http://www.sciencecodex.com/novel-diabetes-drugs-sensitize-cancer-cells-chemotherapy-agents-618082
Insulin glulisine - wikidocInsulin glulisine - wikidoc
A 26-week, randomized, open-label, active-controlled, non-inferiority study was conducted in insulin-treated patients with type 2 diabetes to assess the safety and efficacy of APIDRA (n= 435) given within 15 minutes before a meal compared to regular human insulin (n=441) administered 30 to 45 minutes prior to a meal. NPH human insulin was given twice a day as the basal insulin. All patients participated in a 4-week run-in period with regular human insulin and NPH human insulin. Eighty-five percent of patients were Caucasian and 11% were Black. The mean age was 58 years (range 26 to 84 years). The average body mass index (BMI) was 34.6 kg/m2. At randomization, 58% of the patients were taking an oral antidiabetic agent. These patients were instructed to continue use of their oral antidiabetic agent at the same dose throughout the trial. The majority of patients (79%) mixed their short-acting insulin with NPH human insulin immediately prior to injection. The reductions from baseline in GHb were ...
http://wikidoc.org/index.php/Insulin_glulisine
Report explores the Global oral antidiabetic drugs market: development trends - WhaTechReport explores the Global oral antidiabetic drugs market: development trends - WhaTech
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Oral Antidiabetic Drugs for each application
https://www.whatech.com/market-research/medical/438025-report-explores-the-global-oral-antidiabetic-drugs-market-development-trends
Global Oral Antidiabetic Drugs Market sales is growing at 10.2% CAGR till 2022Global Oral Antidiabetic Drugs Market sales is growing at 10.2% CAGR till 2022
Global oral antidiabetic drug market is expected to reach USD 35.91 billion by 2022, growing at a CAGR of 10.2% between 2017 and 2022.
http://www.sbwire.com/press-releases/oral-antidiabetic-drugs-market/release-780038.htm
Dose-Response Effects of Exercise on Glucose-Lowering Medications for Type 2 Diabetes - Research - RigshospitaletDose-Response Effects of Exercise on Glucose-Lowering Medications for Type 2 Diabetes - Research - Rigshospitalet
Objective: To investigate whether a dose-response relationship exists between volume of exercise and discontinuation of glucose-lowering medication treatment in patients with type 2 diabetes. Patients and Methods: Secondary analyses of a randomized controlled exercise-based lifestyle intervention trial (April 29, 2015 to August 17, 2016). Patients with non-insulin-dependent type 2 diabetes were randomly assigned to an intensive lifestyle intervention (U-TURN) or standard-care group. Both groups received lifestyle advice and objective target-driven medical regulation. Additionally, the U-TURN group received supervised exercise and individualized dietary counseling. Of the 98 randomly assigned participants, 92 were included in the analysis (U-TURN, n=61, standard care, n=31). Participants in the U-TURN group were stratified into tertiles based on accumulated volumes of exercise completed during the 1-year intervention. Results: Median exercise levels of 178 (interquartile range [IQR], 121-213; ...
https://research.regionh.dk/rigshospitalet/en/publications/doseresponse-effects-of-exercise-on-glucoselowering-medications-for-type-2-diabetes
Adding Glucose-Lowering Agents Delays Insulin Initiation and Prolongs HyperglycemiaAdding Glucose-Lowering Agents Delays Insulin Initiation and Prolongs Hyperglycemia
A review of national Veterans Health Administration data has identified how the number of glucose-lowering agents used prior to insulin initiation impacts glycemic control.
http://www.ajmc.com/journals/issue/2016/2016-vol22-n4/adding-glucose-lowering-agents-delays-insulin-initiation-and-prolongs-hyperglycemia?p=2
Older diabetes drugs produced similar glycemic effects as new drugsOlder diabetes drugs produced similar glycemic effects as new drugs
Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. Lund, Søren Søgaard; Tarnow, Lise; Astrup, Anne Sofie; Hovind, Peter; Jacobsen, Peter Karl; Alibegovic, Amra Ciric; Parving, Ida; Pietraszek, Lotte; Frandsen, Merete; Rossing, Peter; Parving, Hans-Henrik; Vaag, Allan Arthur // PLoS Clinical Trials;Oct2008, Vol. 5 Issue 10, Special section p1 Background: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type- 2 diabetes. We investigated the effect of a one-year treatment... ...
http://edc-connection.ebscohost.com/c/articles/31655588/older-diabetes-drugs-produced-similar-glycemic-effects-as-new-drugs
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes...Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes...
Table 1 provides a summary of baseline characteristics, glycemic treatment strategies and goals, concomitant risk factor control, achieved glycemic control, and primary results of each of the three studies. The ACCORD study randomized 10,251 participants with either history of a CVD event (aged 40-79 years) or significant CVD risk (aged 55-79 years with anatomical CVD, albuminuria, left ventricular hypertrophy, or at least two other CVD risk factors) to a strategy of intensive glycemic control (target A1C ,6.0%) or standard glycemic control (target A1C 7.0-7.9%). Investigators used multiple glycemic medications in both arms. ACCORD participants were on average 62 years of age and had a mean duration of diabetes of 10 years, with 35% already treated with insulin at baseline. From a baseline median A1C of 8.1%, the intensive arm reached a median A1C of 6.4% within 12 months of randomization, while the standard group reached a median A1C of 7.5%. Other risk factors were treated aggressively and ...
https://care.diabetesjournals.org/content/32/1/187?ijkey=9abf89b1d7150d345bae4c14254d1571c5d3df01&keytype2=tf_ipsecsha
Diabetes drug Actos associated with lower rates of Alzheimers diseaseDiabetes drug Actos associated with lower rates of Alzheimers disease
A study of over 100,000 people from German healthcare records show the type 2 diabetes drug, pioglitazone, to be linked with lower rates of Alzheimers disease. Actos is in a class of drugs called thiazolidinediones, or TZDs for short. These drugs work by increasing the bodys sensitivity to insulin. Whilst thiazolidinediones have been shown to improve blood glucose control, researchers have been interested to understand whether this has benefits for the brain, particularly with regard to preventing or delaying forms of dementia such as Alzheimers disease.
https://www.diabetes.co.uk/news/2014/jul/diabetes-drug-actos-associated-with-lower-rates-of-alzheimers-disease-91575976.html
Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes...Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes...
Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM) / M.R. Robling, J. Dolben, S.D. Luzio, S. Godtfredsen, D.R. Owens, Steve Luzio ...
https://cronfa.swan.ac.uk/Record/cronfa37868
A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients...A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients...
A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.
https://news.unchealthcare.org/news/2010/December/exenatide
Should You Use a Diabetes Drug to Treat Prediabetes? - DiabetesShould You Use a Diabetes Drug to Treat Prediabetes? - Diabetes
If you have prediabetes, taking the diabetes drug metformin might stop you from getting diabetes and could also help you in other ways. But persuading your doctor to prescribe it could be a challenge.
https://www.healthcentral.com/article/take-metformin-if-you-have-prediabetetes
Diabetes Medicines - Diabetes Drugs & Medicine - Medicine for DiabetesDiabetes Medicines - Diabetes Drugs & Medicine - Medicine for Diabetes
Diabetes Medicines - Buy Diabetes Drugs & Medicine, Know about Diabetes Medicines, What Do Diabetes Medicines Do? Medicines for Type 1 Diabetes, Medicines for Type 2 Diabetes, Medicines for Gestational Diabetes, Medicines for Other Types of Diabetes, Insulin, diabetes pills and injections other than insulin, About side effects of medicines.
https://eshop-rx.com/diabetes-medicines-drugs.aspx
DiVA - Search resultDiVA - Search result
Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovascular mortality and morbidity in new users of SGLT2 inhibitors versus new users of other glucose-lowering drugs, in a population with a broad cardiovascular risk profile. Methods CVD-REAL Nordic was an observational analysis of individual patient-level data from the Prescribed Drug Registers, Cause of Death Registers, and National Patient Registers in Denmark, Norway, and Sweden. All patients who filled a prescription for glucose-lowering drugs between 2012 and 2015 were included and followed up until Dec 31, 2015. Patients were divided into new users of SGLT2 inhibitors and new users of other glucose-lowering drugs. Each SGLT2 inhibitor user was matched with three users of other ...
http://uu.diva-portal.org/smash/resultList.jsf?faces-redirect=true&language=en&searchType=SIMPLE&query=&af=%5B%5D&aq=%5B%5B%7B%22personId%22%3A%22authority-person%3A13635+OR+0000-0002-2639-9481%22%7D%5D%5D&aq2=%5B%5B%5D%5D&aqe=%5B%5D&noOfRows=50&sortOrder=author_sort_asc&sortOrder2=title_sort_asc&onlyFullText=false&sf=all
Study T2 Diabetes Drug Does Not Improve Survival Rates After Breast Cancer | DiabetesCare.netStudy T2 Diabetes Drug Does Not Improve Survival Rates After Breast Cancer | DiabetesCare.net
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new, first-of-its-kind study from Women`s...
http://www.diabetescare.net/article/title/study-t2-diabetes-drug-does-not-improve-survival-rates-after-breast-cancer
Hypoglycemia Up With Intensive Glucose-Lowering Therapy - Drugs.com MedNewsHypoglycemia Up With Intensive Glucose-Lowering Therapy - Drugs.com MedNews
Intensive glucose-lowering therapy is prevalent among U.S. adults with diabetes and results in hospitalizations and emergency department visits for hypoglycemia
https://www.drugs.com/news/hypoglycemia-up-intensive-glucose-lowering-therapy-84560.html
Are These Two Diabetes Drugs Better Than the Others? | Paleo DiabeticAre These Two Diabetes Drugs Better Than the Others? | Paleo Diabetic
The two drugs in question are empagliflozin (aka Jardiance) and liraglutide (aka Victoza). Both are used to treat type 2 diabetes, not type 1. A major problem we have with most diabetes drugs is that while they do lower blood sugars, we dont have much evidence on whether they actually prolong life and prevent bad…
https://paleodiabetic.com/2016/09/06/are-these-two-diabetes-drugs-better-than-the-others/
Health Care Costs Associated With Treatment Modification in Type 2 Diabetes Mellitus Patients Taking Oral Anti-diabetic Drugs |...Health Care Costs Associated With Treatment Modification in Type 2 Diabetes Mellitus Patients Taking Oral Anti-diabetic Drugs |...
Objectives: To compare health care costs among patients with type 2 diabetes mellitus (T2DM) who added a new oral anti-diabetes drug (OAD) to an initial regimen with those who up-titrated their initial OAD.. Methods: Insurance claims data were obtained from 94 health plans for patients aged ≥18 years with ICD-9-CM diagnosis of T2DM during the period Jan. 1, 2001-June 30, 2007, and a newly prescribed metformin or sulfonylurea monotherapy. Patients were followed after initiating monotherapy to identify occurrence of first-treatment modification (addition or up-titration). Health care costs were analyzed during 360 days after first treatment modification. Subgroup analyses included comparison of addition cohort with two titration subgroups: 1) titration up to or below intermediate doses and 2) titration to beyond intermediate doses.. Results: During the post-treatment modification period, all-cause medication costs were 9% higher (p ,0.0001), while inpatient costs were 14% lower for the addition ...
http://www.managedcaremag.com/archives/2011/6/health-care-costs-associated-treatment-modification-type-2-diabetes-mellitus?page=4
Study Shows Less Expensive Diabetes Drug As Effective As Avandia - KLTV.com - Tyler, Longview, Jacksonville |ETX NewsStudy Shows Less Expensive Diabetes Drug As Effective As Avandia - KLTV.com - Tyler, Longview, Jacksonville |ETX News
A new study just out compares diabetes drugs that have been out for years to those supposedly on the cutting edge of medicine.. Many diabetes patients have been taking the more expensive, and newer drug Avandia. But after another study linked it with heart problems, patients looking at older medications have some good news. Avandia, one of the newest drugs, costs hundreds more a month than older drugs. like Glucophage. The good news from a study published in the Annals of Internal Medicine is that Glucophage, the older drug, appears just as effective. Glucophage has been out for about 10 years now, and its generic now which has helped the cost a bit. Its actually one of my first line drugs, says Trinity Mother Frances endocrinologist Dr. Meg Reitmeyer.. She says expensive isnt necessarily better. The study confirms Glucophage doesnt cause weight gain, doesnt cause blood sugar to plummet, and can lower bad cholesterol. The study says it is just as effective at treating diabetes. Meanwhile, ...
http://www.kltv.com/story/6802698/study-shows-less-expensive-diabetes-drug-as-effective-as-avandia
LawyersandSettlements.com Provides Update on Diabetes Drug Lawsuits Involving Januvia, Byetta and ActosLawyersandSettlements.com Provides Update on Diabetes Drug Lawsuits Involving Januvia, Byetta and Actos
Miami, FL (PRWEB) May 23, 2013 -- Although designed to treat Type 2 diabetes, some medications have been involved recently in diabetes drug lawsuits.
http://www.prweb.com/releases/2013/5/prweb10757773.htm
Diabetes Drug May Boost Weight Loss in Obes... ( Combo of diet exercise and injections...)Diabetes Drug May Boost Weight Loss in Obes... ( Combo of diet exercise and injections...)
Health,...Combo of diet exercise and injections helped non-diabetics shed pound...FRIDAY Oct. 23 (HealthDay News) -- The diabetes drug liraglutide help...The study authors also reported that high doses of liraglutide were mo...In the study which included 564 diabetes-free obese patients aged 18 ...,Diabetes,Drug,May,Boost,Weight,Loss,in,Obese,Patients,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
http://www.bio-medicine.org/medicine-news-1/Diabetes-Drug-May-Boost-Weight-Loss-in-Obese-Patients-59975-1/
Diabetes Drugs Weaken Bones - Weight Vest For OsteoporosisDiabetes Drugs Weaken Bones - Weight Vest For Osteoporosis
A study released today and reported in Reuters reveals that diabetes drugs, Avandia and Actos, are bad for your bones.. This study shows that these agents double the risk of fractures in women with type 2 diabetes, who are already at higher risk before taking the therapy, said Sonal Singh of North Carolinas Wake Forest University School of Medicine.. Singh and colleagues at Wake Forest , working with researchers at Britains University of East Anglia, based their findings on a pooled analysis of 10 previous clinical studies lasting at least a year involving 14,000 patients. These drugs are already linked to adverse heart effects including raising the risk of heart failure and carry warning labels for that. I recently bought the dvd, Simply Raw, Reversing Diabetes in 30 Days and I was inspired and impresssed. The 6 participants, from all walks of life, got off as many as 17 medications and insulin in the thirty days in the clinic eating a raw food diet. As you may know, I have diabetes, type ...
https://weightvest4osteoporosis.com/diabetes-drugs-weaken-bones/
Hypoglycemic agent: Definition with Hypoglycemic agent Pictures and PhotosHypoglycemic agent: Definition with Hypoglycemic agent Pictures and Photos
Definition of Hypoglycemic agent with photos and pictures, translations, sample usage, and additional links for more information.
http://www.lexic.us/definition-of/hypoglycemic_agent
New Molecular Connection Between Obesity and Insulin Resistance Brings Hope of Safer Diabetes DrugsNew Molecular Connection Between Obesity and Insulin Resistance Brings Hope of Safer Diabetes Drugs
Researchers have discovered a new molecular link between obesity and the way diabetes drugs work , which may lead to the development of safer medications for diabetes.
http://www.medindia.net/news/New-Molecular-Connection-Between-Obesity-and-Insulin-Resistance-Brings-Hope-of-Safer-Diabetes-Drugs-71842-1.htm
97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL
WASHINGTON, D.C. - (Mealeys) Ninety-seven federal lawsuits in which plaintiffs allege that three incretin-based diabetes drugs caused their pancreatic cancer were centralized Aug. 26 by a federal judicial panel into a multidistrict litigation...
https://www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2013/08/27/97-federal-cases-alleging-cancer-from-diabetes-drugs-centralized-in-mdl.aspx?Redirected=true
Widely Used Type 2 Diabetes Drug May Reduce Cancer Death RiskWidely Used Type 2 Diabetes Drug May Reduce Cancer Death Risk
Metformin, a commonly prescribed diabetes drug, may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, a new study suggests.
https://www.medicinenet.com/script/main/art.asp?articlekey=195004
FDA probes new pancreas risks with diabetes drugs - The Boston GlobeFDA probes new pancreas risks with diabetes drugs - The Boston Globe
The Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems. The agency said Thursday samples of pancreas tissue taken from a small number of patients showed inflammation and cellular changes that often precede cancer. Academic researchers took the samples from diabetes patients who were taking the new medications, after they died from various causes.
https://www.bostonglobe.com/business/2013/03/14/fda-probes-new-pancreas-risks-with-diabetes-drugs/caVHEPEZrRUlgmTM5VcUeI/story.html
Avoiding hypoglycemia: a key to success for glucose-lowering therapy i | VHRMAvoiding hypoglycemia: a key to success for glucose-lowering therapy i | VHRM
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes Bo Ahrén Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, Lund, Sweden Abstract: Type 2 diabetes carries a risk for hypoglycemia, particularly in patients on an intensive glucose control plan as a glucose-lowering strategy, where hypoglycemia may be a limitation for the therapy and also a factor underlying clinical inertia. Glucose-lowering medications that increase circulating insulin in a glucose-independent manner, such as insulin and sulfonylurea therapy, are the most common cause of hypoglycemia. However, other factors such as a delayed or missed meal, physical exercise, or drug or alcohol consumption may also contribute. Specific risk factors for development of hypoglycemia are old age, long duration of diabetes, some concomitant medication, renal dysfunction, hypoglycemia unawareness, and cognitive dysfunction. Hypoglycemia is associated with acute short-term symptoms
https://www.dovepress.com/avoiding-hypoglycemia-a-key-to-success-for-glucose-lowering-therapy-in-peer-reviewed-article-VHRM
Common Diabetes Drug Shows Promise As Lung Cancer Treatment - RedorbitCommon Diabetes Drug Shows Promise As Lung Cancer Treatment - Redorbit
Watch the video Diabetes Drug Could Hold Promise For Lung Cancer Patients Brett Smith for redOrbit.com - Your Universe Online. Scientists have been enthusiastic about the potential use of widely available diabetes drugs to treat various types of cancer. A new study from The Salk Institute for Biological Studies and the David Geffen UCLA School of Medicine suggests that these metabolism-affecting drugs can decrease the size of lung tumors in mice and increase their chances for survival.. According to the study, the diabetes drug phenformin may effectively treat 30 percent of patients with non-small cell lung cancer (NSCLC), a type of cancer with tumors that lack the LKB1 gene.. The LKB1 gene is crucial to every cell´s life cycle as it regulates metabolism by turning on an enzyme called AMPK when levels of the energy molecule ATP are running low within the cell. Previous research by some of the same researchers showed that cells without a normal copy of LKB1 do not activate the AMPK enzyme in ...
http://www.redorbit.com/news/health/1112773857/diabetes-drug-cures-lung-cancer-013013/
Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind,...Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind,...
In the present study two oral antidiabetic agents, a sulfonylurea (glipizide) and a biguanide (metformin), were administrated to non-diabetic African Americans with insulin resistance in a double blind fashion for 24 months. PWV increased significantly in both treatment groups after 24 months. In contrast, PWV remained unchanged in the placebo group. This increase in PWV in glipizide and metformin treated subjects was significant compared with the placebo group. Thus, long term administration of oral antidiabetic glipizide or metformin to normoglycaemic African Americans with insulin resistance may decrease the elastic properties of the aorta. It has been shown previously that increased PWV is an indicator of a high incidence of cardiovascular events and an independent predictor of cardiac mortality.21-25. The cause of this observation is not well understood. The two drugs used in the present study have different mechanisms of action but their glucose lowering effect is generally equivalent. ...
https://heart.bmj.com/content/91/5/589?ijkey=039ff98b84035a610fdf516c7226d85ab3d51e9b&keytype2=tf_ipsecsha
Get Metformin Online | Apps AccelerationGet Metformin Online | Apps Acceleration
buy metformin. metformin generic. metformin online. metformin generic name. metformin price. cost of metformin. generic for metformin. metformin for sale. can you buy metformin over the counter. buy metformin 500 mg. buy metformin 500 mg online. order metformin online. metformin cost without insurance. metformin no prescription. cost of metformin without insurance. order metformin 500 mg online. price of metformin. metformin 1000 mg price. buy metformin 1000 mg. price of metformin without insurance. metformin online pharmacy. buy metformin online uk. metformin price without insurance. order metformin. metformin generic vs brand name. buy metformin online usa. metformin hcl 500 mg price. metformin buy uk. metformin price in india. metformin generic brand. metformin online uk. metformin price at walmart. cost of metformin at walmart. metformin online canada. can you buy metformin online. generic of metformin. buy metformin 1000 mg online. cost of metformin 500 mg. purchase metformin. metformin xr ...
http://appsacceleration.indt.org/get-metformin-online/
Metformin Generic Brands | Apps AccelerationMetformin Generic Brands | Apps Acceleration
buy metformin. metformin generic. metformin online. metformin generic name. metformin price. cost of metformin. generic for metformin. metformin for sale. can you buy metformin over the counter. buy metformin 500 mg. buy metformin 500 mg online. order metformin online. metformin cost without insurance. metformin no prescription. cost of metformin without insurance. order metformin 500 mg online. price of metformin. metformin 1000 mg price. buy metformin 1000 mg. price of metformin without insurance. metformin online pharmacy. buy metformin online uk. metformin price without insurance. order metformin. metformin generic vs brand name. buy metformin online usa. metformin hcl 500 mg price. metformin buy uk. metformin price in india. metformin generic brand. metformin online uk. metformin price at walmart. cost of metformin at walmart. metformin online canada. can you buy metformin online. generic of metformin. buy metformin 1000 mg online. cost of metformin 500 mg. purchase metformin. metformin xr ...
http://appsacceleration.indt.org/metformin-generic-brands/
Buy Metformin Without Doctor | 天蓝Buy Metformin Without Doctor | 天蓝
buy metformin. metformin generic. metformin online. metformin generic name. metformin price. cost of metformin. generic for metformin. metformin for sale. can you buy metformin over the counter. buy metformin 500 mg. buy metformin 500 mg online. order metformin online. metformin cost without insurance. metformin no prescription. cost of metformin without insurance. order metformin 500 mg online. price of metformin. metformin 1000 mg price. buy metformin 1000 mg. price of metformin without insurance. metformin online pharmacy. buy metformin online uk. metformin price without insurance. order metformin. metformin generic vs brand name. buy metformin online usa. metformin hcl 500 mg price. metformin buy uk. metformin price in india. metformin generic brand. metformin online uk. metformin price at walmart. cost of metformin at walmart. metformin online canada. can you buy metformin online. generic of metformin. buy metformin 1000 mg online. cost of metformin 500 mg. purchase metformin. metformin xr ...
http://wp1.ym910.com/archives/156059.htm
Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes - American College of...Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes - American College of...
Following a 4-week run-in period, type 2 diabetics with inadequate glycemic control (hemoglobin [HbA1c], 7-9%) was randomized to rosiglitazone plus metformin or sulfonylurea (n = 2,220; 4 mg/day starting dose of rosiglitazone, uptitrated to 8 mg after 8 weeks) or to metformin plus sulfonylurea (control group; n = 2,227). In the rosiglitazone group, for patients previously on metformin at study entry, sulfonylurea was used for the study regimen; for patients previously on a sulfonylurea at study entry, metformin was used for the study regimen. The criterion for rescue therapy by addition of a third oral agent (if in the rosiglitazone group) or transfer to insulin (in the metformin plus sulfonylurea group) was a confirmed HbA1c of 8.5% or more. ...
https://www.acc.org/latest-in-cardiology/clinical-trials/2010/02/23/19/18/record
Diabetes drug metformin could help lower breast cancer riskDiabetes drug metformin could help lower breast cancer risk
A new study from South Korea has found that the diabetes drug metformin could help to reduce the risk of diabetes-associated cancers, such as breast cancer. The research offers further evidence supporting such benefits of long-term treatment by metformin, which is taken by patients with type 2 diabetes and helps to prevent cardiovascular complications. The team examined if cancers originate from adult stem cells and how many types of chemicals can enhance the growth of breast cancer cells, by growing miniature human breast tumours, called mammospheres, in culture dishes. This activated a stem cell gene, before the mammospheres were exposed to both natural oestrogen and man-made chemicals that can promote tumours or cause problems for the endocrine system.
https://www.diabetes.co.uk/news/2011/Nov/diabetes-drug-metformin-could-help-lower-breast-cancer-risk-98114758.html
Diabetes Drug Metformin May Fight Cancer | Real...Diabetes Drug Metformin May Fight Cancer | Real...
One of the oldest, cheapest, and most widely used diabetes drugs may be a promising new cancer treatment. | Realms of Healthcare and Business
https://www.scoop.it/t/realms-of-medicine-and-business/p/3573970569/2012/12/03/diabetes-drug-metformin-may-fight-cancer
Metformin may lower cancer risk in people with Type ... ( A commonly prescribed diabetes drug ...)Metformin may lower cancer risk in people with Type ... ( A commonly prescribed diabetes drug ...)
Health, ...A commonly prescribed diabetes drug metformin reduces the overall ca... Type 2 diabetes increases the risk for several types of cancer said...Espinoza-Peralta and his colleagues conducted a systematic review and ...The investigators found that the odds of getting any type of cancer wa...,Metformin,may,lower,cancer,risk,in,people,with,Type,2,diabetes,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
http://www.bio-medicine.org/medicine-news-1/Metformin-may-lower-cancer-risk-in-people-with-Type-2-diabetes-91929-1/
NAVER 학술정보 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesNAVER 학술정보 | Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Bo Ahrén Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, Lund, Sweden Abstract: Type 2 diabetes carries a risk for hypoglycemia, particularly in patients on an intensive glucose control plan as a glucose-lowering strategy, where hypoglycemia may be a limitation for the therapy and also a factor underlying clinical inertia. Glucose-lowering medications that increase circulating insulin in a glucose-independent manner, such as insulin and sulfonylurea therapy, are the most common cause of hypoglycemia. However, other factors such as a delayed or missed meal, physical exercise, or drug or alcohol consumption may also contribute. Specific risk factors for development of hypoglycemia are old age, long duration of diabetes, some concomitant medication, renal dysfunction, hypoglycemia unawareness, and cognitive dysfunction. Hypoglycemia is associated with acute short-term symptoms related to either counterregulation, such as tachycardia and sweating, or to neuroglycopenia, such as
http://academic.naver.com/article.naver?doc_id=81460414
Diabetes Drug Infection Lawsuit | Fourniers Gangrene Lawsuit | OnderLaw, LLCDiabetes Drug Infection Lawsuit | Fourniers Gangrene Lawsuit | OnderLaw, LLC
Lawsuits for Genital Infections from Diabetes Drugs If you or a loved one developed a flesh-eating genital infection while taking diabetes drugs, you may be
https://www.onderlaw.com/pharmaceutical-litigation/fourniers-gangrene/necrotizing-fasciitis-lawsuit/
Metformin (Glucophage)Metformin (Glucophage)
Glucophage belongs to a group of medicines called biguanides. Glucophage lowers high blood glucose (hyperglycaemia) by helping your body make better use of the insulin produced by your pancreas. Therapeutic actions: Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may ...
http://click4muscle.com/insulins-biguanides?product_id=287
Diabetes drug metformin inhibits multidrug-resistant breast cancer. ecancer - NewsDiabetes drug metformin inhibits multidrug-resistant breast cancer. ecancer - News
06 Dec 2017. The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published in the open-access journal PLOS ONE by Terra Arnason from the University of Saskatchewan, Canada, and colleagues.. Previous studies have shown that metformin has some antiproliferative activity against multiple types of cancer cells.. Moreover, clinical meta-analysis studies on cancer patients who already take metformin to treat diabetes have hinted that the drug may boost their survival and prevent the emergence of new tumours.. Arnason and colleagues probed the effect of metformin on the widely studied breast cancer cell line MCF7.. Metformin, they found, had an antiproliferative effect on MCF7, including cells that were resistant to the common chemotherapeutic Doxorubicin.. When cells were pretreated with metformin, the development of drug resistance was prevented or ...
http://ecancer.org/news/12950-diabetes-drug-metformin-inhibits-multidrug-resistant-breast-cancer.php
A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when...A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when...
Abstract: Aims To compare the efficacy and safety of either continuing or discontinuing rosiglitazone + metformin fixed-dose combination when starting insulin therapy in people with Type 2 diabetes inadequately controlled on oral therapy.. Methods In this 24-week double-blind study, 324 individuals with Type 2 diabetes inadequately controlled on maximum dose rosiglitazone + metformin therapy were randomly assigned to twice-daily premix insulin therapy (target pre-breakfast and pre-evening meal glucose ≤ 6.5 mmol/l) in addition to either rosiglitazone + metformin (8/2000 mg) or placebo.. Results Insulin dose at week 24 was significantly lower with rosiglitazone + metformin (33.5 ± 1.5 U/day, mean ± se) compared with placebo [59.0 ± 3.0 U/day; model-adjusted difference −26.6 (95% CI −37.7, −15,5) U/day, P < 0.001]. Despite this, there was greater improvement in glycaemic control [HbA1c rosiglitazone + metformin vs. placebo 6.8 ± 0.1 vs. 7.5 ± 0.1%; difference −0.7 (−0.8, −0.5)%, ...
https://scialert.net/asci/ascidetail.php?doi=dmed.2007.618.625&kw=
Metformin | Buy For Fertility | Giladiskon Indonesia - Komunitas Pecinta DiskonMetformin | Buy For Fertility | Giladiskon Indonesia - Komunitas Pecinta Diskon
Looking for a metformin? Not a problem! Buy metformin online ==| http://newcenturyera.com/med/metformin ---- Guaranteed Worldwide Shipping Discreet Package Low Prices 24/7/365 Customer Support 100% Satisfaction Guaranteed. Tags: buy metformin boots where can i buy metformin 500 mg buy metformin online pharmacy purchase metformin er 500mg buy metformin hydrochloride uk buy metformin for pcos online buy metformin online usa order metformin online buy metformin in canada order metformin 500 mg buy metformin online australia where to order metformin without an ex buy metformin over the counter buy metformin buy metformin for pcos online uk metformin get you high buy metformin 850 order metformin uk order metformin from canada order metformin from mexico buy glyburide metformin get metformin prescription buy metformin in usa how to purchase metformin without a script buy metformin online for pcos how to purchase metformin online buy generic metformin online buy metformin online without script buy
http://www.giladiskon.com/forum-topic/metformin-buy-fertility
Diabetes Drug Metformin May Lower Risk of Pancreatic Cancer for Women - CakehealthDiabetes Drug Metformin May Lower Risk of Pancreatic Cancer for Women - Cakehealth
Increasing evidence is suggesting that Type 2 diabetes and pancreatic cancer are somehow linked, but exactly how the link works remains unclear.. A new study may help clarify things - it shows that taking a drug aimed at treating Type 2 diabetes may change a persons risk of developing pancreatic cancer, depending on the drug.. Though some research has shown those with Type 2 diabetes are at an increased risk of developing pancreatic cancer, the new study found that women who took metformin, now the most common treatment for Type 2 diabetes, had a lower risk of pancreatic cancer than the general population. In contrast, women who took drugs from an older class of diabetes treatments, called sulfonylureas, had a higher risk of the cancer, according to the study.. For men, insulin use was linked with a slightly increased risk of pancreatic cancer.. The gender differences surprised the scientists at the University of Basel in Switzerland, who conducted the research. This result is somewhat ...
https://cakehealth.com/2199-diabetes-drug-metformin-pancreatic-cancer-women.html
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in...DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in...
CONTEXT We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes. OBJECTIVE The objective of the study was to compare effects of exenatide once weekly (ExQW) and exenatide twice daily (ExBID) on glycemic control, body weight, and safety. DESIGN This was a 24-wk, randomized, open-label, comparator-controlled study. SETTING The study was conducted at 43 sites in the United States. PATIENTS The study population was 252 intent-to-treat patients with type 2 diabetes [baseline (mean ± SD): glycosylated hemoglobin (HbA1c) 8.4 ± 1.2%, fasting plasma glucose 171 ± 47 mg/dl, weight 96 ± 20 kg] that were drug naïve (19%) or previously treated with one (47%) or multiple (35%) oral antidiabetic medications. INTERVENTIONS Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk. MAIN OUTCOME MEASURE The change in HbA1c from baseline to wk 24 was measured.
https://www.semanticscholar.org/paper/DURATION-5-exenatide-once-weekly-resulted-in-great-Blevins-Pullman/4cd24c90642ccacc52d7ed42469aa11d700cc1e8
Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents<...Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents<...
TY - JOUR. T1 - Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents. AU - Owolabi, BO. AU - Musalea, V. AU - Ojo, OO. AU - Moffett, Charlotte. AU - McGahon, MK. AU - Curtis, TM. AU - Conlon, JM. AU - Flatt, Peter. AU - Abdel-Wahab, YHA. PY - 2017/4/7. Y1 - 2017/4/7. N2 - PGLa-AM1 (GMASKAGSVL10GKVAKVALKA20AL.NH2) was first identified in skin secretions of the frog Xenopus amieti (Pipidae) on the basis of its antimicrobial properties. PGLa-AM1 and its [A14K] and [A20K] analogues produced a concentration-dependent stimulation of insulin release from BRIN-BD11 rat clonal β-cells without cytotoxicity at concentrations up to 3 μM. In contrast, the [A3K] was cytotoxic at concentrations ≥ 30 nM. The potency and maximum rate of insulin release produced by the [A14K] and [A20K] peptides were significantly greater than produced by PGLa-AM1. [A14K]PGLa-AM1 also stimulated insulin release from mouse islets at concentrations ≥ 1 nM and from the ...
https://ulster-staging.pure.elsevier.com/en/publications/actions-of-pgla-am1-and-its-a14k-and-a20k-analogues-and-their-the-3
Metformin and increased cancer survival | CANCERactiveMetformin and increased cancer survival | CANCERactive
Metformin may have several actions against cancer as it reduces blood glucose, inhibits insulin and IGF-1 production, reduces cholesterol and has an indirect effect on reducing m-TOR levels; a specific study on breast cancer suggests increased survival times.. Metformin, or Glucophage, is an anti-hyperglycemic drug which lowers glucose production in the liver and improves uptake of glucose by cells but does not increase insulin production.. In many of the early studies, patients were taking metformin because they had diabetes. One study of women having breast cancer chemotherapy showed 24% of type 2 diabetes patients taking metformin having complete remission, vs 16% non-diabetic patients vs 8% type-2 diabetes patients not taking metformin. In HER2 positive cancer patients taking metformin because of diabetes resulted in 40% lower progression and death after 4.5 years than those not taking metformin.. According to MD Anderson, metformin affects multiple signalling processes to do with growth, ...
https://www.canceractive.com/article/metformin-and%20increased%20cancer%20survival
Sitagliptin - WikipediaSitagliptin - Wikipedia
Sitagliptin (INN; /sɪtəˈɡlɪptɪn/ ( listen), previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed, and is marketed, by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. Side effects are as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for rare nausea and common cold-like symptoms, including photosensitivity. No significant difference exists in the occurrence of hypoglycemia between placebo and sitagliptin. In those taking sulphonylureas, the risk of low blood sugar is increased. The existence of rare case reports of renal failure and hypersensitivity reactions is noted in the United States prescribing ...
https://en.wikipedia.org/wiki/Sitagliptin
Three common diabetes drugs could boost chances of dying | EmaxHealthThree common diabetes drugs could boost chances of dying | EmaxHealth
In findings presented at The Endocrine Societys 94th Annual Meeting in Houston, scientists presented evidence that the generic diabetes drug metformin is linked to a lower chance of mortality, compared to 3 other drugs that are known as sulfonylureas - glipizide, glyburide, and glimepiride.. Kevin M. Pantalone, D.O., an endocrinologist at Summa Western Reserve Hospital in Cuyahoga Falls, Ohio, who conducted this study in collaboration with researchers from Cleveland Clinic said in a press release, We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea.. For the study, researchers looked at electronic medical records of 23,915 patients with type 2 diabetes who had taken one of the four drugs in the past. Average age of people in the study was 62 and half of the participants were male. ...
https://www.emaxhealth.com/1020/three-common-diabetes-drugs-could-boost-chances-dying
Diabetes drug may kill cancer stem cells, study says | Genetic Literacy ProjectDiabetes drug may kill cancer stem cells, study says | Genetic Literacy Project
Results from a new study suggest low doses of the diabetes drug metformin may effectively destroy pancreatic cancer stem cells, reducing the risk of tumor growth or recurrence.
https://geneticliteracyproject.org/2012/06/22/diabetes-drug-may-kill-cancer-stem-cells-study-says/
Effects of insulin sensitizing drug metformin on clinical features, endocrine and metabolic profiles in obese women with...Effects of insulin sensitizing drug metformin on clinical features, endocrine and metabolic profiles in obese women with...
Use of metformin seems to improve reproductive and metabolic abnormalities in women with PCOS. However, the disparity of results in clinical studies cannot give us a conclusive answer if metformin is a new line therapy of the syndrome. The present randomised, placebo-controlled study was designed to compare the antihyperglycemic drug metformin vs. placebo combined with lifestyle modification in the treatment of polycystic ovary syndrome in obese women. Special attention was paid to the effects of this medication on insulin and glucose metabolism, endocrine and biochemical parameters, and menstrual function. Forty six obese women with PCOS, aged between 22-39 years and mean BMI 38.1 were randomized to receive either metformin (500 mg three times a day for 16 weeks) or placebo. The metformin and placebo groups were matched for age, endocrinological and metabolic parameters. Changes in FSH, LH, estradiol, testosterone, DHEA-S and SHBG, total cholesterol, triglycerides, insulin, glucose, HbA1c, ...
https://edoc.hu-berlin.de/handle/18452/16283
Overview of Type 2 Diabetes Drugs on the MarketOverview of Type 2 Diabetes Drugs on the Market
Type 2 Diabetes Mellitus (T2DM) is a systemic metabolic disorder with complex pathogenesis. In recent years, a variety of new T2DM drugs have emerged, such as sodium-dependent glucose transporters 2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. As traditional medicines, insulin also has developed kinds of formulations such as quick-acting or premixed insulin. In addition, new treatment schedules combining multiple drugs are also fully explored. The efficacy, the administration, the mechanism, the safety and the price of these drugs are all different, providing patients with multiple options. This paper reviews the main types of type 2 diabetes drugs on the market and describes the mechanism of action. The representative type 2 diabetes treatment drugs are listed, and the advantages and disadvantages of these representative drugs are preliminarily evaluated. This information is reviewed to help doctors with clinical medication.
https://m.scirp.org/papers/102005
African Americans Respond Better to First-line Diabetes Drug than Whites - Healthcanal.com : Healthcanal.comAfrican Americans Respond Better to First-line Diabetes Drug than Whites - Healthcanal.com : Healthcanal.com
Washington, DC-African Americans taking the diabetes drug metformin saw greater improvements in their blood sugar control than white individuals who were prescribed the same medication, according to a new study published in the Endocrine Societys Journal of Clinical Endocrinology & Metabolism (JCEM). An estimated 29 million Americans have diabetes. African Americans are twice as likely to be diagnosed with diabetes as whites and have a higher rate of complications such as kidney failure, according to the U.S. Department of Health and Human Services Office of Minority Health. Metformin is the most common oral medication prescribed for diabetes. It decreases the amount of glucose produced by the liver and helps the body respond better to insulin, the hormone that helps carry sugar from the bloodstream into cells. Metformin is normally the first treatment physicians prescribe for type 2 diabetes, but the standard of care is based on clinical trials where the vast majority of participants were ...
https://www.healthcanal.com/metabolic-problems/diabetes/51925-african-americans-respond-better-to-first-line-diabetes-drug-than-whites.html
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats | GutLimited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats | Gut
Aim: Peroxisome proliferator activated receptor γ (PPARγ) agonists have been shown to prevent hepatic fibrosis in rodents. We evaluated the therapeutic antifibrotic potential of the PPARγ agonist pioglitazone on established hepatic fibrosis.. Methods: Repeated injections of carbon tetrachloride (CCl4), a choline deficient diet, or bile duct ligation (BDL) were used to induce hepatic fibrosis in rats. Pioglitazone treatment was introduced at various time points. Therapeutic efficacy was assessed by comparison of the severity of hepatic fibrosis in pioglitazone treated versus untreated fibrotic controls.. Results: When introduced after two weeks of CCl4, pioglitazone reduced hepatic fibrosis, OH proline content, hepatic mRNA expression of collagen type I, and profibrotic genes, as well as the number of activated α smooth muscle actin positive hepatic stellate cells, compared with rats receiving CCl4 only, with no significant change in necroinflammation. When pioglitazone treatment was ...
http://gut.bmj.com/content/55/7/1020
Europe Antidiabetics Market: Know The Current and Future Prospects of the Industry from 2017 To 2022 | BusinessEurope Antidiabetics Market: Know The Current and Future Prospects of the Industry from 2017 To 2022 | Business
Additionally, in Europe Antidiabetics Market Report, development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.. No. of Report Pages:122. Price of Report (Single User Licence): $3900. Purchase Europe Antidiabetics Market Research Report at: http://www.absolutereports.com/purchase/10626097. About Absolute Reports:. Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.. Contact-. Mr. Ameya Pingaley. Absolute Reports. +1-408 520 9750. Email - [email protected] ...
http://beforeitsnews.com/business/2017/03/europe-antidiabetics-market-know-the-current-and-future-prospects-of-the-industry-from-2017-to-2022-3197389.html
Glucose-lowering therapies, adequacy of metabolic control, and their r | DMSOGlucose-lowering therapies, adequacy of metabolic control, and their r | DMSO
Glucose-lowering therapies, adequacy of metabolic control, and their relationship with comorbid depression in outpatients with type 2 diabetes in a tertiary hospital in Kenya CF Frederick Otieno,1 Joseph E Kanu,1 Emma M Karari,1 Violet Okech-Helu,2 Mark D Joshi,1 Kenn Mutai2 1Department of Clinical Medicine and Therapeutics, University of Nairobi, 2Kenyatta National Hospital, Nairobi, Kenya Background: Depression and diabetes mellitus are important comorbid conditions with serious health consequences. When depression and diabetes are comorbid, depression negatively affects self-management activities of diabetes with serious consequences. Relationship between treatment regimens of diabetes, the adequacy of glycemic control, and occurrence of comorbid depression is not known among our patients.Patients and methods: This was a cross-sectional descriptive study at the outpatient diabetes clinic of the Kenyatta National Hospital where 220 ambulatory patients with type 2 diabetes on follow-up were
https://www.dovepress.com/glucose-lowering-therapies-adequacy-of-metabolic-control-and-their-rel-peer-reviewed-article-DMSO
Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth | Cancer ResearchSystemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth | Cancer Research
Recent population-based studies of type 2 diabetes patients have reported that metformin treatment is associated with a reduced cancer incidence and mortality ( 19, 20). Here, we investigated whether metformin has a direct effect on growth of HCT116 colon cancer cells in vivo. We report that treatment with either metformin or AICAR, two known activators of AMPK, reduces tumor growth in xenografts of HCT116 cells deficient for p53. In contrast, metformin and AICAR have little to no effect on the growth of xenografts of HCT116 p53+/+ cells. This selectivity correlated with the ability of HCT116 and untransformed MEFs to engage in a p53-dependent metabolic response that promoted cell survival.. p53 is a tumor suppressor that is often mutated in cancer. In response to genotoxic stresses, p53 induces a transcriptional response that can result in cell cycle arrest, senescence, or apoptosis. However, a recent study revealed a prosurvival role for p53 in cells metabolically impaired by glucose ...
https://cancerres.aacrjournals.org/content/67/14/6745?ijkey=5d45447dc08257a83de1c1e3c7f8fef6da849037&keytype2=tf_ipsecsha
ADA: Cardiovascular Benefits Seen With Long-Term Metformin Use In Adults With Type 1 Diabetes | DiabetesTalk.NetADA: Cardiovascular Benefits Seen With Long-Term Metformin Use In Adults With Type 1 Diabetes | DiabetesTalk.Net
Home / Conditions / Type 1 Diabetes / ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease am
https://diabetestalk.net/popular/ada-cardiovascular-benefits-seen-with-long-term-metformin-use-in-adults-with-type-1-diabetes
Diabetes Drug Amaryl Genezen 2 Type Te - bestcities bestDiabetes Drug Amaryl Genezen 2 Type Te - bestcities best
Nearly 30 million people have diabetes in America and the price for the lifesaving drug insulin tripled in a 10-year period. Diabetes Drug Amaryl Genezen 2 Type Te skin Discoloration Diabetes Prediabetes Risk Assessment; Type 2 Diabetes Yogurt; Signs Of Juvenile Diabetes In Toddlers; Is Cottage Cheese Good For Diabetics; According to Ayurveda diabetes is not just lack of insulin. What is Diabetes? For more information on how type 1 and type 2 However nobody is still in agreement on a common diagnostic tool in acute pancreatitis. The 1500 calorie ADA (American Diabetic Association) diet is designed primarily for those individuals who are overweight and suffering from diabetes.. Current studies suggest that 50% to 70% of women with PCOS have some degree of insulin resistance.10. by The behavior of eating more is in response to the hormonal signal to get fat. Those who skip critical blood glucose testing because of the price tag on a box of strips may soon get a eak.. For example diabetic ...
http://www.bestcities.eu/best/diabetes-drug-amaryl-genezen-2-type-te/
AID 1083661 - Antihyperglycemic activity in albino Rattus norvegicus Sprague-Dawley (rat) streptozotocin-induced diabetic model...AID 1083661 - Antihyperglycemic activity in albino Rattus norvegicus Sprague-Dawley (rat) streptozotocin-induced diabetic model...
BioAssay record AID 1083661 submitted by ChEMBL: Antihyperglycemic activity in albino Rattus norvegicus Sprague-Dawley (rat) streptozotocin-induced diabetic model assessed as effect on AUC of blood glucose level at 100 mg/kg, po after 24 hr.
https://pubchem.ncbi.nlm.nih.gov/bioassay/1083661
Managing type 2 diabetes - Medical IndependentManaging type 2 diabetes - Medical Independent
Early initiation of pharmacologic therapy is associated with improved glycaemic control and reduced long-term complications in type 2 diabetes. There are multiple drug classes used for the treatment of type 2 diabetes.. Biguanides. Metformin lowers basal and postprandial plasma glucose levels by decreasing hepatic gluconeogenesis production, slowing intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilisation. Unlike oral sulfonylureas, metformin rarely causes hypoglycaemia and is the only oral diabetes drug that facilitates modest weight loss. In addition, the UK Prospective Diabetes Study (UKPDS) demonstrated that it was successful at reducing macrovascular disease in obese patients.. Sulfonylureas. Sulfonylureas stimulate insulin release from pancreatic beta cells and enhance peripheral sensitivity to insulin secondary to an increase in insulin receptors or to changes in the events following insulin-receptor binding. Sulfonylureas ...
https://www.medicalindependent.ie/managing-type-2-diabetes/
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of...Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of...
The antidiabetic drug metformin exhibits potential anticancer properties that are believed to involve both direct (insulin-independent) and indirect (insulin-dependent) actions. Direct effects are linked to activation of AMP-activated protein kinase (AMPK) and an inhibition of mammalian target of rapamycin mTOR signaling, and indirect effects are mediated by reductions in circulating insulin, leading to reduced insulin receptor (IR)-mediated signaling. However, the in vivo impact of metformin on cancer cell signaling and the factors governing sensitivity in patients remain unknown. We conducted a neoadjuvant, single-arm,
https://0-breast--cancer--research-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/s13058-015-0540-0
FDA OKs First-of-a-Kind Diabetes Drug - Memphis Daily NewsFDA OKs First-of-a-Kind Diabetes Drug - Memphis Daily News
WASHINGTON (AP) - The Food and Drug Administration says it has approved a first-of-a-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar.. The agency cleared J&Js Invokana tablets for adults with Type 2 diabetes, which affects about 26 million Americans.. The drug is a once-a-day medicine designed to lower blood sugar levels in patients by eliminating more sugar in their urine. The drug works by blocking the reabsorption of sugar by the kidneys, which occurs at higher levels in patients with diabetes.. J&J has touted the drug as the first in a new class of medications to help address the nations growing diabetes epidemic. The drug differs from older drugs that work by decreasing the amount of sugar absorbed from food and stored in the liver.. Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.. ...
https://www.memphisdailynews.com/news/2013/apr/1/fda-oks-first-of-a-kind-diabetes-drug/print
FDA Testing Levels of Carcinogens in Diabetes Drug Metformin - Be part of the knowledge ...FDA Testing Levels of Carcinogens in Diabetes Drug Metformin - Be part of the knowledge ...
UPI.com Levels of possible cancer-causing chemicals in metformin diabetes medications are under investigation by the U.S. Food and Drug Administration. Metformin is a prescription drug used to control high blood sugar in patients with type 2 diabetes. Over the past year and a half, several types of drugs -- including angiotensin II receptor blockers, or ARBs, used for high blood pressure and ranitidine, marketed as Zantac, for heartburn -- have been found to contain small amounts of genotoxic substances called nitrosamines, such as N-nitrosodimethylamine, or NDMA. A genotoxic substance is something that harms the genetic material in a cell. Exposure to genotoxic substances above acceptable levels over long periods may increase the risk of cancer, the FDA said. The FDA has been investigating the presence of nitrosamines in other drug products, and some metformin diabetes medicines in other countries were reported to have low levels of NDMA, according to Dr. Janet Woodcock, director of FDAs Center
https://www.reachmd.com/news/fda-testing-levels-of-carcinogens-in-diabetes-drug-metformin/1630666/
FDA: Two diabetes drugs may be linked to heart failure riskFDA: Two diabetes drugs may be linked to heart failure risk
(HealthDay)-Diabetes drugs containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, U.S. health officials warned Tuesday.
https://medicalxpress.com/news/2016-04-fda-diabetes-drugs-linked-heart.html
How Drug Combination Helps Control Type 1 Diabetes | THE DIABETICS BLOGHow Drug Combination Helps Control Type 1 Diabetes | THE DIABETICS BLOG
Drug derived from gila monster saliva helps diabetics control glucose, lose weight date: july 12, 2007 source: university of north carolina at chapel hill. The u.s. food and drug administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults. The u.s. food and drug administration (fda) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause.. A new type of medication for type 2 diabetes helps to lower blood sugar levels when used in concert with insulin and other diabetes drugs, new research. Read more on metformin; sulphonylureas. sulphonylureas are the class of antidiabetic drug for type 2 diabetes that tends to include those drugs which end in ide.. Actos (pioglitazone) is an oral diabetes medicine that helps control blood sugar levels. actos is for people with type 2 diabetes. pioglitazone is not for treating.. Free weekly newsletter ezine and web site dedicated to ...
http://www.diabetescurativesecrets.com/how-drug-combination-helps-control-type-1-diabetes
DPP-4 Inhibitor Diabetes Drugs Side Effects Risks - Crohns Disease (CD)DPP-4 Inhibitor Diabetes Drugs Side Effects Risks - Crohns Disease (CD)
DPP-4 inhibitor diabetes drugs such as Januvia, Onglyza, and Kombiglyze increase the risk of Crohns Disease according to a recent medical journal article.
https://www.lamblawoffice.com/dpp-4-inhibitor-diabetes-drugs-class-side-effect-crohns-disease-cd/
Use of antidepressants in diabetes patients not using drugs, but only monitoring blood glucoseUse of antidepressants in diabetes patients not using drugs, but only monitoring blood glucose
ABSTRACT. Objective: Patients with diabetes have an increased Odds Ratio (OR) for depressive disorder. We wanted to investigate if patients with metabolic syndrome and/or diabetes type 2 not treated with antidiabetic agents, have an OR for concurrent antidepressant use comparable to other types of diabetes. Methods: Drug delivery data from 25 pharmacies were analysed with respect to sale of antidepressants, oral antidiabetic agents, insulin and blood glucose test strips. Results: Total population of the area was 337,019, whereas 254,083 were 18 or older. Of these 20,139 were patients receiving insulin, oral antidiabetics, glucose test strips and/or antidepressants. Those receiving antidepressants were 5.8% of those 18 or older whereas 2.4% received any antidiabetic medication (including test strips for HBGM). For patients receiving no medications but test strips alone, the adjusted OR for use concurrent use of antidepressants was 1.62 (95% confidence interval: 1.19 - 2.23), p = 0.002. For ...
https://file.scirp.org/Html/13-4300071_19363.htm
ISMP Questions Overall Safety of Type 2 Diabetes Drug, Invokana | New York Legal Examiner | New York New York Personal Injury...ISMP Questions Overall Safety of Type 2 Diabetes Drug, Invokana | New York Legal Examiner | New York New York Personal Injury...
Reports of problems with type 2 diabetes drug Invokana (canagliflozin) have continued to increase, according to the Institute for Safe Medicine Practices...
http://newyork.legalexaminer.com/defective-dangerous-products/ismp-questions-overall-safety-of-type-2-diabetes-drug-invokana/
Type-2 Diabetes Drug Curbs Heart Failure Risk in PatientsType-2 Diabetes Drug Curbs Heart Failure Risk in Patients
A Type-2 diabetes drug has the potential to prevent hospitalizations due to heart failure in diabetic patients who never had the condition before.
http://www.medindia.net/news/type-2-diabetes-drug-curbs-heart-failure-risk-in-patients-155377-1.htm
WHO Model List of Essential MedicinesWHO Model List of Essential Medicines
Oral hypoglycaemic agents[edit]. *Gliclazide[note 74]. *Metformin. *Metforminα. Medicines for hypoglycaemia[edit]. *Glucagon ... Lipid-lowering agents[edit]. *Simvastatin[note 72]. Dermatological medicines (topical)[edit]. Antifungal medicines[edit]. * ... Diagnostic agents[edit]. *Tuberculin, purified protein derivative (PPD). Sera and immunoglobulins[edit]. *Antivenom ... single agent trimethoprim may be an alternative for lower urinary tract infection. ...
https://en.wikipedia.org/wiki/List_of_World_Health_Organization_Essential_Medicines
MetforminMetformin
"Hypoglycemic Agents. I Chemical Properties of β-Phenethylbiguanide. A New Hypoglycemic Agent". J Am Chem Soc. 81 (9): 2220-25. ... Davis SN (2006). "Chapter 60: Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas". In Brunton L ... Jia Y, Lao Y, Zhu H, Li N, Leung SW (January 2019). "Is metformin still the most efficacious first-line oral hypoglycaemic drug ... Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E (January 2009). "Benefits and risks of oral diabetes agents compared ...
https://en.wikipedia.org/wiki/Metformin
BuforminBuformin
... and the other biguanides are not hypoglycemic, but rather antihyperglycemic agents. They do not produce hypoglycemia; ... "Hypoglycemic Agents. III.1-3N1-Alkyl- and Aralkylbiguanides". Journal of the American Chemical Society. 81 (14): 3728-3736. doi ... Shroff JR, Bandurco V, Desai R, Kobrin S, Cervoni P (December 1981). "Chemistry and hypoglycemic activity of ... Marchetti P, Giannarelli R, di Carlo A, Navalesi R (October 1991). "Pharmacokinetic optimisation of oral hypoglycaemic therapy ...
https://en.wikipedia.org/wiki/Buformin
Glossary of diabetesGlossary of diabetes
See also: Oral hypoglycemic agents. One of the sulfonylureas. (Amaryl) Glipizide A pill taken to lower the level of glucose ( ... See also: Oral hypoglycemic agents. (Tolinase) Tolbutamide A pill taken to lower the level of glucose (sugar) in the blood. ... See also: Oral hypoglycemic agents. This is one of the sulfonylureas (Diabinese). Cholesterol a waxy substance related to the ... See also: Oral hypoglycemic agents. One of the sulfonylureas. (Diamicron) Glimepiride A pill taken to lower the level of ...
https://en.wikipedia.org/wiki/Glossary_of_diabetes
EnglitazoneEnglitazone
... is a hypoglycemic agent of thiazolidinedione (glitazone) class. Ciglitazone Darglitazone Netoglitazone Troglitazone ...
https://en.wikipedia.org/wiki/Englitazone
HydroxychloroquineHydroxychloroquine
It enhances hypoglycemic effects of insulin and oral hypoglycemic agents. Dose altering is recommended to prevent profound ... Both agents also inhibit CYP2D6 activity and may interact with other medications that depend on this enzyme. Antimalarials are ... wherein it may enhance the effects of a hypoglycemic treatment) Drugs that prolong QT interval and other arrhythmogenic drugs ( ... "Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents". ...
https://en.wikipedia.org/wiki/Hydroxychloroquine
OxandroloneOxandrolone
... can also inhibit the metabolism of oral hypoglycemic agents. It may worsen edema when taken alongside ... Oxandrolone is sometimes used as a doping agent in sports. Cases of doping with oxandrolone by professional athletes have been ... Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science ...
https://en.wikipedia.org/wiki/Oxandrolone
1,3-Butanediol1,3-Butanediol
In biology, 1,3-butanediol is used as a hypoglycaemic agent. 1,3-Butanediol can be converted into β-hydroxybutyrate and serve ...
https://en.wikipedia.org/wiki/1,3-Butanediol
RimonabantRimonabant
1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation". Journal of Medicinal Chemistry. 32 (2): ...
https://en.wikipedia.org/wiki/Rimonabant
GlibenclamideGlibenclamide
Marble A (1971). "Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?". Drugs. 1 (2): 109-15. doi:10.2165/ ... Agents Chemother. 50 (12): 4214-6. doi:10.1128/AAC.00617-06. PMC 1693980. PMID 17015627. Ortega FJ, Gimeno-Bayon J, Espinosa- ...
https://en.wikipedia.org/wiki/Glibenclamide
MethylprednisoloneMethylprednisolone
In patients with diabetes, increased requirements of insulin or oral hypoglycemic agents. Fluid and electrolyte disturbances: ...
https://en.wikipedia.org/wiki/Methylprednisolone
GlimepirideGlimepiride
Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas". In Brunton, Laurence L.; Lazo, John S.; ... coumadin and probenecid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretics, phothiazides, ...
https://en.wikipedia.org/wiki/Glimepiride
PancreatitisPancreatitis
There are various oral hypoglycemic agents that contributes to pancreatitis including metformin. But, glucagon-like peptide-1 ( ... and oral hypoglycemic agents. Mechanisms of these drugs causing pancreatitis are not known exactly; but it is possible that ... A number of infectious agents have been recognized as causes of pancreatitis including: Viruses Coxsackie virus Cytomegalovirus ...
https://en.wikipedia.org/wiki/Pancreatitis
PrulifloxacinPrulifloxacin
Hypoglycemic agents: May cause hypoglycemia in diabetic patients under treatment with hypoglycemic agents. Theophylline: May ... Quinolones are synthetic agents that have a broad spectrum of antimicrobial activity as well as a unique mechanism of action, ... Agents Chemother. 37 (2): 293-6. doi:10.1128/AAC.37.2.293. PMC 187655. PMID 8452360. Keam, Susan J; Perry, Caroline M (2004). " ... Giannarini G, Tascini C, Selli C (2009). "Prulifloxacin: clinical studies of a broad-spectrum quinolone agent". Future ...
https://en.wikipedia.org/wiki/Prulifloxacin
NetoglitazoneNetoglitazone
... (also called MCC-555) is a hypoglycemic agent belonging to the thiazolidinedione group. Lazarenko OP, Rzonca SO, ...
https://en.wikipedia.org/wiki/Netoglitazone
MODY 4MODY 4
None were severely insulin-deficient and all were controlled with either diet or oral hypoglycemic agents. v t e Stoffers, ...
https://en.wikipedia.org/wiki/MODY_4
PinoresinolPinoresinol
... inhibits the enzyme α-glucosidase in vitro and may therefore act as a hypoglycemic agent. A study involving extra ... Pinoresinol is a putative hypoglycemic agent in defatted sesame (Sesamum indicum) seeds though inhibiting α-glucosidase". ...
https://en.wikipedia.org/wiki/Pinoresinol
Maturity onset diabetes of the youngMaturity onset diabetes of the young
When oral hypoglycemic agents are used in MODY, the sulfonylureas remain the oral medication of first resort. When compared to ... Standard diabetes treatments (insulin for type 1 and gestational diabetes, and oral hypoglycemic agents for type 2) are often ... oral hypoglycemic agents, and insulin injections. In many cases these goals can be achieved more easily with MODY than with ... Insulin may not be necessary and it may be possible to switch a person from insulin injections to oral agents without loss of ...
https://en.wikipedia.org/wiki/Maturity_onset_diabetes_of_the_young
BiguanideBiguanide
... s do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. ... and bisbiguanide agents for antiplaque activity". Antimicrobial Agents and Chemotherapy. 12 (6): 721-9. doi:10.1128/aac.12.6. ...
https://en.wikipedia.org/wiki/Biguanide
VincristineVincristine
... and in the Philippines and South Africa as a oral hypoglycemic agent - but not as a treatment for cancer. Catharanthus roseus ... Treatment of the ground plant with Skelly-B defatting agent and an acid benzene extract led to a fraction termed "fraction A". ... Anti-Cancer Agents. 2 (1): 1-17. doi:10.2174/1568011023354290. PMID 12678749. Silverman JA, Deitcher SR (March 2013). "Marqibo ... Johnson IS, Armstrong JG, Gorman M, Burnett JP (September 1963). "The Vinca Alkaloids: A New Class of Oncolytic Agents" (PDF). ...
https://en.wikipedia.org/wiki/Vincristine
Beta cellBeta cell
... islet hormones and hypoglycemic agents". Biochemical and Biophysical Research Communications. 179 (1): 1-9. doi:10.1016/0006- ...
https://en.wikipedia.org/wiki/Beta_cell
KetonuriaKetonuria
In addition, when diabetic treatment is being switched from insulin to oral hypoglycemic agents, the patient's urine should be ... of ketonuria within 24 hours after insulin withdrawal usually indicates a poor response to the oral hypoglycemic agents. ...
https://en.wikipedia.org/wiki/Ketonuria
Hyperinsulinemic hypoglycemiaHyperinsulinemic hypoglycemia
Management of hypoglycemia due to treatment of type 2 diabetes is similar, and the dose of the oral hypoglycemic agent may need ... Knowing that someone takes insulin or oral hypoglycemic agents for diabetes obviously makes insulin excess the presumptive ...
https://en.wikipedia.org/wiki/Hyperinsulinemic_hypoglycemia
Insulin (medication)Insulin (medication)
The basic appeal of hypoglycemic agents by mouth is that most people would prefer a pill or an oral liquid to an injection. ... The abuse of exogenous insulin carries with it an attendant risk of hypoglycemic coma and death when the amount used is in ... The affected persons are then switched to a preparation that does not contain the specific agent they are reacting to or ... The limitations are cost, the potential for hypoglycemic and hyperglycemic episodes, catheter problems, and no "closed loop" ...
https://en.wikipedia.org/wiki/Insulin_(medication)
Diabetes medicationDiabetes medication
... all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are ... Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct ... First-generation agents tolbutamide acetohexamide tolazamide chlorpropamide Second-generation agents glipizide glyburide or ... These agents slow the digestion of starch in the small intestine, so that glucose from the starch of a meal enters the ...
https://en.wikipedia.org/wiki/Diabetes_medication
Diabetic nephropathyDiabetic nephropathy
Glycemic control is maintained mainly with insulin in patients with Type 1 DM and with hypoglycemic agents and/or insulin in ... it is recommended that only one agent is used in patients with DM who have hypertension or any signs of microalbuminuria or ... Although RAAS blockade using more than one agent may further reduce proteinuria, the risk of adverse events (such as ... or that they are experiencing an increasing frequency of hypoglycemic episodes. It is also crucial to closely monitor kidney ...
https://en.wikipedia.org/wiki/Diabetic_nephropathy
Dihydroxymalonic acidDihydroxymalonic acid
It has been used in medical research as a hypoglycemic agent and was patented in the United States in 1997 as a fast-acting ... Yoshito KOBAYASHI, Shigeru OHASHI, Shinzaburo TANAKA and Akitoshi SHIOYA (1955), Hypoglycemic Action of Sodium Mesoxalate with ...
https://en.wikipedia.org/wiki/Dihydroxymalonic_acid
IpragliflozinIpragliflozin
... were both observed in a Phase III study in monotherapy and clinical studies used in combination with other hypoglycemic agents ...
https://en.wikipedia.org/wiki/Ipragliflozin
List of MeSH codes (D27)List of MeSH codes (D27)
... hypoglycemic agents MeSH D27.505.696.477 - immunologic factors MeSH D27.505.696.477.136 - agglutinins MeSH D27.505.696.477. ... antiviral agents MeSH D27.505.954.122.388.077 - anti-retroviral agents MeSH D27.505.954.122.388.077.088 - anti-hiv agents MeSH ... tocolytic agents MeSH D27.505.954.016 - anti-allergic agents MeSH D27.505.954.122 - anti-infective agents MeSH D27.505.954.122. ... tranquilizing agents MeSH D27.505.696.277.950.015 - anti-anxiety agents MeSH D27.505.696.277.950.025 - antimanic agents MeSH ...
https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D27)
Peroxisome proliferator-activated receptor gammaPeroxisome proliferator-activated receptor gamma
... are currently studied with the hope that such compounds would be still effective hypoglycemic agents but with fewer side ... Many naturally occurring agents directly bind with and activate PPAR gamma. These agents include various polyunsaturated fatty ...
https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_gamma
Momordica charantiaMomordica charantia
... anthelmintic agent, for the treatment of cough, respiratory diseases, skin diseases, wounds, ulcer, gout, and rheumatism.[8] ... several animal studies and small-scale human studies have demonstrated a hypoglycemic effect of concentrated bitter melon ... "cannot be recommended as a replacement therapy for insulin or hypoglycemic drugs".[9] ... "Gene cloning and expression of a novel hypoglycaemic peptide from Momordica charantia". Journal of the Science of Food and ...
https://en.m.wikipedia.org/wiki/Bitter_melon
NMDA receptorNMDA receptor
Common agents in which NMDA receptor antagonism is the primary or a major mechanism of action: *4-Chlorokynurenine (AV-101) - ... The purpose was to develop a hypoglycemic drug, but it showed no such efficacy. It was not until 1972 that a possible ... Some common agents in which weak NMDA receptor antagonism is a secondary or additional action include: *Amantadine - an ... Tramadol - an atypical opioid analgesic and serotonin releasing agent. Nitromemantine[edit]. The NMDA receptor is regulated via ...
https://en.wikipedia.org/wiki/NMDA_receptor
ಟೆಂಪ್ಲೇಟು:Central nervous system navs - ವಿಕಿಪೀಡಿಯಟೆಂಪ್ಲೇಟು:Central nervous system navs - ವಿಕಿಪೀಡಿಯ
These are geared towards lay readers, not readers who are technically proficient. Do not replace easy to understand lay variants (e.g. "smell") with difficult variants lay readers will not understand (e.g. "olfaction ...
https://kn.wikipedia.org/wiki/ಟೆಂಪ್ಲೇಟು:Central_nervous_system_navs
1,3-Butanediol1,3-Butanediol
In biology, 1,3-butanediol is used as a hypoglycaemic agent. 1,3-Butanediol can be converted into β-hydroxybutyrate and serve ...
https://en.wikipedia.org/wiki/E1502
Blood sugar levelBlood sugar level
Hypoglycemic episodes can vary greatly between persons and from time to time, both in severity and swiftness of onset. For ... Drugs: salicylates, antituberculosis agents Hyperthyroidism Acute stress reaction Hypopituitarism Severe liver disease ...
https://en.wikipedia.org/wiki/Blood_sugar
Jelly BabiesJelly Babies
A popular school chemistry experiment, is to put them in one strong oxidising agent, and see the resulting spectacular reaction ... its content alluding to the consumption of jelly babies by Type 1 Diabetics to overcome hypoglycaemic episodes - as a way to ...
https://en.m.wikipedia.org/wiki/Jelly_Babies
Dipeptidyl peptidase-4 inhibitorDipeptidyl peptidase-4 inhibitor
Inhibitors of dipeptidyl peptidase 4, also DPP-4 inhibitors or gliptins, are a class of oral hypoglycemics that block DPP-4 ( ... DPP-IV). They can be used to treat diabetes mellitus type 2. The first agent of the class - sitagliptin - was approved by the ... How do they work as new antidiabetic agents?". Regulatory Peptides. 128 (2): 159-65. doi:10.1016/j.regpep.2004.06.001. PMID ... is one of the mechanisms explaining the hypoglycemic effect of berberine". Journal of Enzyme Inhibition and Medicinal Chemistry ...
https://en.wikipedia.org/wiki/Dipeptidyl_peptidase-4_inhibitor
TaurineTaurine
According to animal studies, taurine produces an anxiolytic effect and may act as a modulator or antianxiety agent in the ... Winiarska K, Szymanski K, Gorniak P, Dudziak M, Bryla J (February 2009). "Hypoglycaemic, antioxidative and nephroprotective ... Taurine reacts with these halogenating agents to form N-chloro- and N-bromotaurine, which are less toxic than their precursors ...
https://en.m.wikipedia.org/wiki/Taurine
BreastfeedingBreastfeeding
Breastmilk also makes a child resistant to insulin, which is why they are less likely to be hypoglycemic. Infants are more ... Anti inflammatory agents in breast milk. *Areola. *Areolar gland (gland of Montgomery) ...
https://en.wikipedia.org/wiki/Breast-feeding
Toxic leukoencephalopathyToxic leukoencephalopathy
Some reversibility of the condition has been seen in many cases when the toxic agent is removed. Various pharmacological agents ... Hypoglycaemic encephalopathy is often seen in diabetics as a result to accidental overdose with the long-acting sulfonylurea ... However, no such agent has been identified; and indeed, toxic leukoencephalopathy has been observed as a result of intoxication ... Despite the pharmacological agent or source of toxicity, some patients completely recover from toxic leukoencephalopathy. Due ...
https://en.wikipedia.org/wiki/Toxic_leukoencephalopathy
Diabetic neuropathyDiabetic neuropathy
Topical agents[edit]. Capsaicin applied to the skin in a 0.075% concentration has not been found to be more effective than ... However, such methods may increase the likelihood of experiencing a hypoglycemic event, and many of these more aggressive ... This can lead to hypoglycemia when an oral diabetic agent is taken before a meal and does not get absorbed until hours, or ... Blood vessel opening agents (e.g., ACE inhibitors, α1-antagonists) can lead to substantial improvements in neuronal blood flow ...
https://en.wikipedia.org/wiki/Diabetic_neuropathy
Ophiocordyceps unilateralisOphiocordyceps unilateralis
... with corresponding discovery of small molecule agents (e.g. of the polyketide family) of potential interest for use as human ... hypoglycemic, and hypocholesterolemic targets.[14] ... for the production of substances active as antibacterial agents ...
https://en.wikipedia.org/wiki/Ophiocordyceps_unilateralis
Drug interactionDrug interaction
Some drugs, such as the prokinetic agents increase the speed with which a substance passes through the intestines. If a drug is ... This will block the reaction triggered by the catecholamines should a hypoglycaemic episode occur. Therefore, the body will not ...
https://en.wikipedia.org/wiki/Drug_interaction
Therapeutic effectTherapeutic effect
A 2015 review found that aloe vera exhibits therapeutic antioxidant, antimicrobial, immune boosting, antitumor, hypoglycemic, ... both responses are behavioral/physiologic changes that occur as a response to the treatment strategy or agent. To maximize ...
https://en.wikipedia.org/wiki/Therapeutic_effect
Yacón syrupYacón syrup
... is a sweetening agent extracted from the tuberous roots of the yacón plant (Smallanthus sonchifolius) indigenous to ... Aybar, Manuel J.; Sánchez Riera, Alicia N.; Grau, Alfredo; Sánchez, Sara S. (February 2001). "Hypoglycemic effect of the water ...
https://en.wikipedia.org/wiki/Yacón_syrup
J. P. YadavJ. P. Yadav
2012). Activity of Medicinal Plants Against Isolates of Oral Cancer Cases Medicinal Plants Role As Antimicrobial Agents. Yadav ... ISBN 978-3-659-14921-4. Genetic diversity and hypoglycemic studies of Salvadora species. LAP LAMBERT Academic Publishing GmbH ... 2013). Genetic diversity and hypoglycemic studies of Salvadora species. Yadav, Jaya Parkash. (1. Aufl ed.). Saarbrücken: LAP ...
https://en.wikipedia.org/wiki/J._P._Yadav
Insulin shock therapyInsulin shock therapy
Patients required continuous supervision as there was a danger of hypoglycemic aftershocks after the coma. In "modified insulin ... insulin was not the specific therapeutic agent. In 1958, Bourne published a paper on increasing disillusionment in the ...
https://en.wikipedia.org/wiki/Insulin_shock_therapy
Theilers diseaseTheiler's disease
Horses are rarely hypoglycemic, but blood glucose monitoring is ideal to indicate which horses may be benefited by glucose ... so additional causative factors such as immune mediated hypersensitivity or co-infections with other agents may be required to ... This condition most commonly occurs after the administration of a horse origin biological agent such as equine-derived ...
https://en.wikipedia.org/wiki/Theiler's_disease
List of Casualty specialsList of Casualty specials
They are interrupted by a homeless man who needs emergency treatment when he goes into a hypoglycaemic coma. Young wanted to ... received a phone call from his agent, before he had read the script, and she informed him of the use of a horse. However, after ...
https://en.wikipedia.org/wiki/List_of_Casualty_specials
Patent US5567713 - Hypoglycemic agents - Google PatentsPatent US5567713 - Hypoglycemic agents - Google Patents
... preserving agents, sweetening agents, perfuming agents, stabilizing agents or flavoring agents. The formulations of the ... Oral hypoglycemic agents are normally used in the treatment of adult onset diabetes. ... Also contemplated as within the scope of the present invention is concomitant treatment with oral hypoglycemic agents, insulin ... The introduction of orally effective hypoglycemic agents was an important development in the treatment of hyperglycemia. ...
http://www.google.com/patents/US5567713?dq=6,108,703
Diabetes - Oral Hypoglycemic Agents and Glycemic ControlDiabetes - Oral Hypoglycemic Agents and Glycemic Control
Initiating a Patient in Oral Hypoglycemic Agents (OHA). Treatment for type 2 diabetes is usually started with an older agent. ... Diabetes - Oral Hypoglycemic Agents and Glycemic Control Do you wish to consult Diabetologist for your problem? Ask your ... Diabetes - Oral Hypoglycemic Agents and Glycemic Control - Related News. *Conceiving in Winter can Increase Risk of Gestational ... Pramlintide is not an oral hypoglycemic agent per se, since is given in diabetes patients as an injection in the abdomen or ...
https://www.medindia.net/patients/patientinfo/diabetes-oral-hypoglycemic-agents-and-glycemic-control.htm?utm_source=medindia&utm_medium=footerwidget&utm_content=&utm_campaign=relatedtopics
MedlinePlus - Search Results for: Hypoglycemic agentsMedlinePlus - Search Results for: Hypoglycemic agents
ClinicalTrials.gov: Hypoglycemic Agents (National Institutes of Health) Diabetes Medicines/Clinical Trials ... Diabetes ... and Kidney Diseases,/p, ,/ content , , content name =" mesh ", Hypoglycemic Agents ,/ content , , content name =" mesh ", ...
https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&v%3Asources=medlineplus-bundle&query=Hypoglycemic+agents&_ga=2.23606841.247026034.1552925651-263769861.1544059313
Downloadable Document - Hypoglycemic Agents | GreenMedInfo | NaturalDownloadable Document - Hypoglycemic Agents | GreenMedInfo | Natural
162 Curated Medical Research astracts associated with Hypoglycemic Agents. FRIEND membership. $8 / month $75 / year FRIEND USER ... PRO MEMBERS get Unlimited Access to downloadable documents like this, with curated research on Hypoglycemic Agents. ... Some Example Abstracts on Hypoglycemic Agents. Electrolyzed reduced water (i.e. structured water) protects against pancreatic ... Hypoglycemic Agents : CK(1446) : AC(342), Insulin Antagonists : CK(10) : AC(1), Peptide YY (PYY) Down-regulation : CK(10) : AC( ...
http://www.greenmedinfo.com/product/downloadable-document-hypoglycemic-agents
Metformin: the safest hypoglycaemic agent in chronic kidney disease?Metformin: the safest hypoglycaemic agent in chronic kidney disease?
Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the ... Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118(4):c380-3. doi: 10.1159/ ... Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the ...
https://pubmed.ncbi.nlm.nih.gov/21325870/?dopt=Abstract
Oral hypoglycaemic agents in 118 diabetic pregnancies. - PubMed - NCBIOral hypoglycaemic agents in 118 diabetic pregnancies. - PubMed - NCBI
Oral hypoglycaemic agents in 118 diabetic pregnancies.. Hellmuth E1, Damm P, Mølsted-Pedersen L. ... To assess maternal and neonatal complications in pregnancies of diabetic women treated with oral hypoglycaemic agents during ...
https://www.ncbi.nlm.nih.gov/pubmed/10972579
Oral Hypoglycemic AgentsOral Hypoglycemic Agents
... acute toxic effects have been known to follow the use of these oral hypoglycemic agents. There is no doubt that these agents ... Oral Hypoglycemic Agents. Support our website, and your well being, by purchasing our 2380 pages megabook. Raw Food Explained: ... 9. Oral Hypoglycemic Agents. Often, oral medication is given to diabetics instead of insulin to control the symptoms. It is ...
https://www.rawfoodexplained.com/carbohydrate-metabolism-disease/part-i-diabetes-mellitus/oral-hypoglycemic-agents.html
Diabetes - Oral Hypoglycemic Agents and Glycemic Control - Frequently Asked Questions / FAQsDiabetes - Oral Hypoglycemic Agents and Glycemic Control - Frequently Asked Questions / FAQ's
Oral Hypoglycemic Agents and Glycemic Control. This and other commonly asked questions about this condition. ... Diabetes - Oral Hypoglycemic Agents and Glycemic Control - Frequently Asked Questions Do you wish to consult Diabetologist for ... Diabetes - Oral Hypoglycemic Agents and Glycemic Control - Related News. *Diabetes - The Alarming Facts - Interview With Dr. V ...
https://www.medindia.net/patients/patientinfo/diabetes-oral-hypoglycemic-agents-and-glycemic-control-faqs.htm
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic...Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic...
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic ... Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic ... The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of oral hypoglycemic agents that decrease the ... Metformin is the preferred initial agent for the treatment of type 2 diabetes, and an additional second-line agent is often ...
https://www.hindawi.com/journals/jdr/2018/6807219/
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family MedicineEfficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family Medicine
Compared agent. Other hypoglycemic agent or placebo. Long-term health outcomes. All-cause mortality, micro- or macrovascular ... Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus. Nancy J. Lee, Susan L. Norris and Sujata ... Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus Message Subject (Your Name) has sent you a ... Severe Hypoglycemic Events in Placebo-Controlled Trials of Pramlintide in Type 1 Diabetes ...
https://www.annfammed.org/content/8/6/542/tab-figures-data
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family MedicineEfficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family Medicine
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus. Nancy J. Lee, Susan L. Norris and Sujata ... It is estimated that more than 50% of patients with type 2 diabetes will require more than 1 oral hypoglycemic agent 3 years ... with or without oral hypoglycemic agents,9 had significantly greater improvement in HbA1c levels with pramlintide than placebo ... and harms of pramlintide in adults and children with type 1 or type 2 diabetes compared to oral hypoglycemic agents, insulin, ...
https://www.annfammed.org/node/2015.full.print
Oral hypoglycaemic agents | Springer for Research & DevelopmentOral hypoglycaemic agents | Springer for Research & Development
A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19, ... Circadian variation of glucose, insulin and free fatty acids during longterm use of oral hypoglycaemic agents in diabetes ...
https://rd.springer.com/article/10.1007/BF02947552
Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome | CochraneHypoglycaemic agents for pregnant women with polycystic ovarian syndrome | Cochrane
Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome. This review has been withdrawn. ... Ismail KMK, Issa BG, Jones P, Hanna FW, Indusekhar R. Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome ...
https://www.cochrane.org/CD009828/PREG_hypoglycaemic-agents-pregnant-women-polycystic-ovarian-syndrome
Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic...Post-hoc analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic...
... analyses of type 2 diabetes patients switch from premixed insulin regimen to basal insulin plus oral hypoglycemic agents ... Several subjects from the premixed arm experienced too frequent hypoglycemic episodes to be recorded during 10AM-11AM almost ... proved hypoglycemic episodes 94 (76%) vs 21 (47%), chi(2) = 23.692, P , 0.01], The frequency of hypoglycemia before lunch was ... hypoglycemic episodes were significantly higher in premixed-insulin-treated subjects than in glargine-treated subjects [total: ...
https://www.ncbi.nlm.nih.gov/pubmed/18269868?dopt=Abstract
Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy | Diabetes CareEffects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy | Diabetes Care
Troglitazone, developed as a drug to enhance insulin action, can be a useful hypoglycemic agent for the treatment of NIDDM. ... OBJECTIVE To investigate the clinical efficacy of troglitazone, a newly developed oral hypoglycemic agent, in patients with ... Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. ... Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy ...
http://care.diabetesjournals.org/content/19/2/151
CiNii 論文 - The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese...CiNii 論文 - The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese...
The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats * * Nakano Ryosuke NAKANO ... The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice SHIMAYA A ... Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in ... Hypoglycemic Agent YM440 Ameliorates the Impaired Hepatic Glycogenesis After Glucose Loading by Increasing Glycogen Synthase ...
https://ci.nii.ac.jp/naid/10018236505
Polycystic Ovarian Syndrome Medication: Hypoglycemic Agents, Antiandrogens, Topical Hair-Removal Agents, Oral Contraceptives,...Polycystic Ovarian Syndrome Medication: Hypoglycemic Agents, Antiandrogens, Topical Hair-Removal Agents, Oral Contraceptives,...
Acne Agents, Topical. Class Summary. Various topical over-the-counter (OTC) and prescription agents are available to treat acne ... Antiandrogen agents block androgen receptors, thereby inhibiting the effects of male sex hormones. These agents may be used to ... Leuprolide is not a first-line agent in PCOS and therefore is not used often for this syndrome. This agent suppresses ovarian ... Finasteride tends to be a second-line agent for hirsutism in PCOS, when hirsutism persists despite the use of first-line agents ...
https://emedicine.medscape.com/article/256806-medication
Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus - Full Text...Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus - Full Text...
Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (Vit C). The ... Type 2DM patients receiving oral hypoglycemic agents alone this group is the control group who receive oral hypoglycemic agents ... Hypoglycemic Agents. Glyburide. Micronutrients. Growth Substances. Physiological Effects of Drugs. Antioxidants. Molecular ... Experimental: Vitamin C supplementation plus oral hypoglycemic agents arm This group will receive vitamin C supplementation ...
https://clinicaltrials.gov/ct2/show/NCT01319734?recr=Open&intr=%22Ascorbic+Acid%22&rank=19
Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D...Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D...
2. We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in ... a novel oral hypoglycaemic agent is a non-sulphonylurea insulin secretagogue. ... Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D- ... 1. (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166), a novel oral hypoglycaemic agent is a non- ...
https://pubmed.ncbi.nlm.nih.gov/9117089/?dopt=Abstract
Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus |...Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus |...
Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. ... It is unclear whether patients with type 2 diabetes who have poor glycaemic control despite maximal oral hypoglycaemic agents ( ... Simple application of a single daily insulin injection in addition to oral hypoglycaemic agents may facilitate the initiation ... Bedtime NPH insulin combined with oral hypoglycaemic agents provides comparable glycaemic control to insulin monotherapy and is ...
https://www.cochrane.org/CD003418/ENDOC_insulin-monotherapy-versus-combinations-of-insulin-with-oral-hypoglycaemic-agents-in-patients-with-type-2-diabetes-mellitus
Hypoglycemic agent: Definition with Hypoglycemic agent Pictures and PhotosHypoglycemic agent: Definition with Hypoglycemic agent Pictures and Photos
Definition of Hypoglycemic agent with photos and pictures, translations, sample usage, and additional links for more ... hypoglycaemic agent. hypoglycaemic agents. hypoglycaemic coma. hypoglycemia. hypoglycemias. hypoglycemic. hypoglycemic agent ( ... Hypoglycemic Agent Images Lexicographical Neighbors of Hypoglycemic Agent. hypoglossal nucleus. hypoglossal trigone. ... Exact synonyms: Hypoglycaemic Agent. Specialized synonyms: Orinase, Tolbutamide, Insulin. Generic synonyms: Agent. ...
http://www.lexic.us/definition-of/hypoglycemic_agent
Review: inhaled insulin provides better glycaemic control than oral hypoglycaemic agents but not better than subcutaneous...Review: inhaled insulin provides better glycaemic control than oral hypoglycaemic agents but not better than subcutaneous...
Review: inhaled insulin provides better glycaemic control than oral hypoglycaemic agents but not better than subcutaneous ... Review: inhaled insulin provides better glycaemic control than oral hypoglycaemic agents but not better than subcutaneous ...
http://ebn.bmj.com/content/10/2/49.full?related-urls=yes&legid=ebnurs
A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment.A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment.
... vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment., lker Boyraz, Ugur Bilge, ... A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment.. ... Distinctively from other similar studies, the level of 25(OH) Vitamin D in T2DM patients taking oral hypoglycemic agents (OHAs ... Type 2 DM, Oral hypoglycemic agents (OHAs), Insulin, 25(OH) Vitamin D. ...
http://www.alliedacademies.org/articles/a-comparison-of-25oh-vitamin-d-levels-in-patients-with-type-2-diabetes-on-oral-hypoglycemic-agents-and-insulin-treatment.html
Hypoglycemic Agents | Colorado PROFILESHypoglycemic Agents | Colorado PROFILES
"Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these ... "Hypoglycemic Agents" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents". ...
https://profiles.ucdenver.edu/display/205529
HYPOG - Clinical: Hypoglycemic Agent Screen, SerumHYPOG - Clinical: Hypoglycemic Agent Screen, Serum
Therefore, in the evaluation of the hypoglycemic patient, the possible use of oral hypoglycemic agents as the cause for low ... Absence of hypoglycemic drugs in blood serum during an episode of low blood glucose should be demonstrated before considering ... Therefore, in the evaluation of the hypoglycemic patient, the possible use of oral hypoglycemic agents as the cause for low ... Use of hypoglycemic agents outside of the context of treatment of type 2 diabetes is likely to cause hypoglycemia associated ...
https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/82439
Gamadiabet - Hypoglycemic Agents, Sulfonylureas, ATC:A10BB31Gamadiabet - Hypoglycemic Agents, Sulfonylureas, ATC:A10BB31
... similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas. ...
http://pharmacycode.com/Gamadiabet.html
Onmel (Itraconazole Oral Administration): Uses, Dosage, Side Effects, Interactions, WarningOnmel (Itraconazole Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
Oral Hypoglycemic Agents. Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and ... Blood glucose concentrations should be carefully monitored when ONMEL and oral hypoglycemic agents are coadministered. ... Oral Hypoglycemics. oral hypoglycemics (repaglinide). Opiate Analgesics. fentanyl, levacetylmethadol (levomethadyl), methadone ... Anti-HIV Agents. indinavir, ritonavir. *This list is not all-inclusive.. † For information on parenterally administered ...
https://www.rxlist.com/onmel-drug.htm
Plus itPlus it
... antacids or acid-suppressing agents, lipid-lowering agents, antiplatelet agents or anticoagulants, oral hypoglycemic agents and ... Oral hypoglycemic agents. Diabetes mellitus is increasingly seen in HIV-infected individuals, especially as this population ... Certain classes of oral hypoglycemic agents are metabolized via the CYP450 system and may be susceptible to interactions with ... Such medications include antidepressants, oral hypoglycemic agents and warfarin.. Antidepressants. Most antidepressants, ...
http://www.cmaj.ca/content/187/1/36
Hypoglycemic Agent Poisoning | 5-Minute Emergency ConsultHypoglycemic Agent Poisoning | 5-Minute Emergency Consult
Hypoglycemic Agent Poisoning answers are found in the 5-Minute Emergency Consult powered by Unbound Medicine. Available for ... Hypoglycemic Agent Poisoning is a topic covered in the 5-Minute Emergency Consult. To view the entire topic, please sign in or ... "Hypoglycemic Agent Poisoning." 5-Minute Emergency Consult, 5th ed., Lippincott Williams & Wilkins, 2016. Emergency Central, ... Hypoglycemic Agent Poisoning [Internet]. In: 5-Minute Emergency Consult. Lippincott Williams & Wilkins; 2016. [cited 2018 ...
https://emergency.unboundmedicine.com/emergency/view/5-Minute_Emergency_Consult/307653/all/Hypoglycemic_Agent_Poisoning
WHO Model List of Essential Medicines - WikipediaWHO Model List of Essential Medicines - Wikipedia
Oral hypoglycaemic agents[edit]. *Gliclazide[note 74]. *Metformin. *Metforminα. Medicines for hypoglycaemia[edit]. *Glucagon ... Lipid-lowering agents[edit]. *Simvastatin[note 72]. Dermatological medicines (topical)[edit]. Antifungal medicines[edit]. * ... Diagnostic agents[edit]. *Tuberculin, purified protein derivative (PPD). Sera and immunoglobulins[edit]. *Antivenom ... single agent trimethoprim may be an alternative for lower urinary tract infection. ...
https://en.wikipedia.org/wiki/List_of_World_Health_Organization_Essential_Medicines
Glycemic ControlTreated with oral hypoglycaemic agentsDiabetesSulfonylureaOHAsHypoglycemiaDrugsInhibitorsEfficacySulfonylureasMechanism of actMetforminAntidiabeticBiguanidesGlycaemic controlMedicationHyperglycemiaGlipizide2016MetabolismSubstancesMechanismsSecretionComaTherapeuticAntiplatelet agentsOral agentSerumPatientsIMSEARMeshReduce blood glucose levelsEffectPolycystic ovarianBlood
Glycemic Control7
  • Refill adherence to oral hypoglycemic agents and glycemic control in veterans. (nih.gov)
  • OUR GENERAL RESEARCH HYPOTHESIS IS THAT: in pregnant women with gestational diabetes mellitus, using both oral hypoglycemic agents (glyburide added to metformin if needed) allows a glycemic control comparable to the one obtained with insulin, but with a better acceptability from women and a better health status, diabetes treatment satisfaction and well-being and a reduced postnatal depression. (clinicaltrials.gov)
  • In addition to strict glycemic control, use of systemic agents in other therapeutic classes, such as candesartan and fenofibrate, can delay the progression of DR in patients with type 2 diabetes [ 6 , 7 ]. (hindawi.com)
  • 1 4 5 6 7 25 27 29 30 Patients initially receiving an oral antidiabetic agent will eventually require multiple oral antidiabetic agents of different therapeutic classes and/or insulin for adequate glycemic control because of declining β 2 -cell function with disease progression. (drugs.com)
  • If adequate blood glucose control is not attained using a single oral agent, a combination of agents with different mechanisms of action may have additive therapeutic effects and result in better glycemic control. (aafp.org)
  • Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. (bvsalud.org)
  • Demographic data , usage of hypoglycemic agents and level of glycemic control were collected to determine the pattern ofuse, associated factors, and achievement of glycemic control . (bvsalud.org)
Treated with oral hypoglycaemic agents1
  • To assess maternal and neonatal complications in pregnancies of diabetic women treated with oral hypoglycaemic agents during pregnancy. (nih.gov)
Diabetes30
  • Oral hypoglycemic agents are normally used in the treatment of adult onset diabetes. (google.com)
  • Oral hypoglycemic drugs or oral diabetic medications or diabetes pills are of several types drugs in each group act in a different way to bring about blood glucose control. (medindia.net)
  • Gestational Diabetes: Insulin or Oral Hypoglycemic Agents? (clinicaltrials.gov)
  • Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. (nih.gov)
  • Among several SGLT2i, empagliflozin and dapagliflozin are now available in Korea, and clinicians usually recommended its use in combination with other hypoglycemic agents as a second- or third-line therapy for type 2 diabetes [ 11 ]. (hindawi.com)
  • It is estimated that more than 50% of patients with type 2 diabetes will require more than 1 oral hypoglycemic agent 3 years from diagnosis and that approximately 70% will require combination oral therapy with or without insulin by 6 to 9 years. (annfammed.org)
  • The purpose of this systematic review is to assess the efficacy, effectiveness, and harms of pramlintide in adults and children with type 1 or type 2 diabetes compared to oral hypoglycemic agents, insulin, or placebo. (annfammed.org)
  • Circadian variation of glucose, insulin and free fatty acids during longterm use of oral hypoglycaemic agents in diabetes mellitus. (springer.com)
  • 1970. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. (springer.com)
  • Simple application of a single daily insulin injection in addition to oral hypoglycaemic agents may facilitate the initiation of insulin therapy in type 2 diabetes mellitus.This review examined 20 trials including 1,811 participants which compared insulin monotherapy with insulin in combination with oral hypoglycaemic agents (OHA) in insulin-requiring patients with type 2 diabetes. (cochrane.org)
  • It is unclear whether patients with type 2 diabetes who have poor glycaemic control despite maximal oral hypoglycaemic agents (OHAs) should be commenced on insulin as monotherapy, or insulin combined with oral hypoglycaemic agents (insulin-OHA combination therapy). (cochrane.org)
  • Any of various agents that decrease the level of glucose in the blood and are used in the treatment of diabetes mellitus. (lexic.us)
  • A comparison of 25(OH) vitamin D levels in patients with type 2 diabetes on oral hypoglycemic agents and insulin treatment. (alliedacademies.org)
  • The aim of this study was to compare the levels of 25(OH) Vitamin D in patients with type 2 diabetes mellitus (T2DM), taking oral hypoglycemic (OHA) medications and insulin. (alliedacademies.org)
  • Use of hypoglycemic agents outside of the context of treatment of type 2 diabetes is likely to cause hypoglycemia associated with elevated plasma insulin. (mayocliniclabs.com)
  • Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. (pharmacycode.com)
  • In this discussion, we will focus on the efficacy and safety of oral hypoglycemic agents in the management of type 2 diabetes in children. (lecturio.com)
  • Insulin and other hypoglycemic agents are used to treat diabetes mellitus. (drugtimes.org)
  • Thomas Higgins, M.D. Oral hypoglycemic drugs are used only in the treatment of type 2 diabetes which is a disorder involving resistance to. (jimdo.com)
  • Sulfonylurea agents or "oral hypoglycemic agents" are one of six types of diabetes pills currently available to treat type 2 diabetes. (jimdo.com)
  • Oral Agents in the Management of Type 2 Diabetes Mellitus. (jimdo.com)
  • Oral hypoglycemic pills are a class of prescription medications used to control diabetes. (jimdo.com)
  • Diabetes control can be achieved by employing a combination of diet and oral hypoglycaemic agents. (nowvningboe.info)
  • The global diabetes drug market has reached $83 billion, of which DPP-4 inhibitor oral hypoglycemic drug market exceeds $20 billion. (tidepharm.com)
  • The approval of this important oral hypoglycemic agent will further strengthen and consolidate the predominant position of Tide Pharmaceutical in the field of diabetes. (tidepharm.com)
  • It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (rcsb.org)
  • To determine the pattern of hyperglycemic agent usage in Thai type 2 diabetics (T2 DM) who attended the diabetes clinic in university and tertiary-care hospitals . (bvsalud.org)
  • 6. Explain the limitations of oral hypoglycemics in management of diabetes. (powershow.com)
  • The American Diabetes Association and the American College of Physicians both recommend metformin as a first-line agent to treat type 2 diabetes. (wikipedia.org)
  • The United Kingdom Prospective Diabetes Study, a large clinical trial performed in 1980-90s, provided evidence that metformin reduced the rate of adverse cardiovascular outcomes in overweight patients with type 2 diabetes relative to other antihyperglycemic agents. (wikipedia.org)
Sulfonylurea3
  • Insulin, indeed, can remedy these 2 etiologies, but it is logical to think about using oral hypoglycemic agents which have been created to treat them: they are a natural choice because they improve insulin sensitivity (metformin, a biguanide) or insulin secretion (glyburide, a sulfonylurea). (clinicaltrials.gov)
  • Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. (nih.gov)
  • Glibenclamide belongs to the second generation oral sulfonylurea drugs with the mechanism of action being similar as tolbutamide and the hypoglycemic effect being strongest among sulfonylurea drugs. (chemicalbook.com)
OHAs4
  • Distinctively from other similar studies, the level of 25(OH) Vitamin D in T2DM patients taking oral hypoglycemic agents (OHAs) will be compared with those taking insulin by means of metabolic parameters. (alliedacademies.org)
  • Introduction Oral Agents General Considerations Oral Hypoglycemic Agents (OHAs) Oral Hyperglycemic Agents (AHAs) Sulfonylureas Preliminary Study of the Clinical Hypoglycemic Effects of Allium cepa (Red Onion) in Type 1 and Type 2 Diabetic Patients. (jimdo.com)
  • ORAL HYPOGLYCEMIC AGENTS (OHAs) Oral medication is initiated when 2-3 months of diet and exercise alone are unable to achieve or maintain their optimal plasma glucose. (jimdo.com)
  • The consumption of oral hypoglycemic agents (OHAs) for the period of 2008 - 2013 at the Ukrainian market has been analyzed. (edu.ua)
Hypoglycemia3
  • Patients presenting with hypoglycemia due to ingestion of a first-, second-, or third-generation hypoglycemic agent will have drug present in serum greater than the minimum effective concentration (see Reference Values). (mayocliniclabs.com)
  • Which medications in the drug class Insulin secretion inhibiting agents are used in the treatment of Pediatric Hypoglycemia? (medscape.com)
  • Metformin has a lower risk of hypoglycemia than the sulfonylureas, although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose. (wikipedia.org)
Drugs8
  • These are called oral hypoglycemic drugs, in other words, drugs that reduce blood glucose levels. (medindia.net)
  • This article gives an insight on why oral hypoglycemic drugs are prescribed and how they act. (medindia.net)
  • How Do Oral Hypoglycemic Drugs Work? (medindia.net)
  • Absence of hypoglycemic drugs in blood serum during an episode of low blood glucose should be demonstrated before considering pancreatic exploration for suspected insulinoma. (mayocliniclabs.com)
  • Blood serum is the specimen of choice for detecting use of the hypoglycemic drugs: urine or plasma is not an acceptable specimen. (mayocliniclabs.com)
  • 7 Relative to HIV-infected patients under 50 years of age, older HIV patients are substantially more likely to be receiving additional medications, including cardiovascular drugs, antacids or acid-suppressing agents, lipid-lowering agents, antiplatelet agents or anticoagulants, oral hypoglycemic agents and erectile dysfunction drugs. (cmaj.ca)
  • Drugs used for lowering the glucose level in the blood are called hypoglycemic agents. (drugtimes.org)
  • Oral hypoglycaemic agents are drugs which are employed to help lower the elevated blood glucose level. (nowvningboe.info)
Inhibitors1
  • The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of oral hypoglycemic agents that decrease the reabsorption of glucose in the renal proximal tubules [ 8 , 9 ]. (hindawi.com)
Efficacy4
  • OBJECTIVE To investigate the clinical efficacy of troglitazone, a newly developed oral hypoglycemic agent, in patients with NIDDM. (diabetesjournals.org)
  • however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas. (pharmacycode.com)
  • Options for monotherapy and combination therapy, efficacy of specific agents, adverse effects and special populations are some issues addressed in this review. (aafp.org)
  • being applicable for patients of high blood sugar who get bad efficacy when treated with other sulfonyl Urea hypoglycemic agents. (chemicalbook.com)
Sulfonylureas1
  • Oral Hypoglycemic agents History In contrast to the systematic studies that led to the isolation of insulin, the sulfonylureas were discovered accidentally. (jimdo.com)
Mechanism of act1
  • If the HbA1c target is not achieved within 3 months of initiating dual therapy , a third agent with a complementary mechanism of action can be added for triple combination therapy . (bvsalud.org)
Metformin4
  • Metformin: the safest hypoglycaemic agent in chronic kidney disease? (nih.gov)
  • Bedtime NPH insulin combined with oral hypoglycaemic agents provides comparable glycaemic control to insulin monotherapy and is associated with less weight gain if metformin is used. (cochrane.org)
  • More than 60% of the patients treated with metformin monotherapy had body mass index (BMI) of more than 25 kg/m2, as compare to less than half of patient treated with other monotherapy agent. (bvsalud.org)
  • Metformin is a biguanide antihyperglycemic agent. (wikipedia.org)
Antidiabetic1
  • Effect of the new oral antidiabetic agent(-)-BM 13.0913. (nii.ac.jp)
Biguanides2
  • There are 2 types of oral hypoglycaemic agents: Sulphonylureas and the Biguanides. (nowvningboe.info)
  • Buformin and the other biguanides are not hypoglycemic, but rather antihyperglycemic agents. (wikipedia.org)
Glycaemic control1
  • The results suggest that a bedtime NPH insulin-oral hypoglycaemic agent combination therapy regimen provides comparable glycaemic control to insulin monotherapy. (cochrane.org)
Medication2
  • Modern combination antiretroviral therapy consists of at least three antiretroviral agents and leads to virologic suppression in most patients who are able to take their medication regularly. (cmaj.ca)
  • An oral hypoglycemic agent is a medication (usually a pill or capsule) that can be take by mouth to lower a high blood sugar toward normal. (jimdo.com)
Hyperglycemia1
  • The introduction of orally effective hypoglycemic agents was an important development in the treatment of hyperglycemia. (google.com)
Glipizide1
  • Chlorpropamide is twice as potent as the related second-generation agent glipizide. (pharmacycode.com)
20161
  • 2016. https://emergency.unboundmedicine.com/emergency/view/5-Minute_Emergency_Consult/307653/all/Hypoglycemic_Agent_Poisoning. (unboundmedicine.com)
Metabolism1
  • Alkylating agents are used to treat cancer because they interfere with cell metabolism and growth. (tabers.com)
Substances1
  • Likewise, substances that raise the level of glucose in the blood are called hyperglycemic agents. (drugtimes.org)
Mechanisms2
  • 1 In an effort to slow disease progression, there has been a concerted effort to develop newer pharmacologic agents with alternate mechanisms of action and minimal harms. (annfammed.org)
  • 8. Understand the different mechanisms of action between the commonly used oral hypoglycemic agents. (powershow.com)
Secretion1
  • 6. Simultaneous measurement of plasma insulin levels revealed that the hypoglycaemic effect of A-4166 was caused by a rapid-onset and brief burst of insulin secretion. (nih.gov)
Coma1
  • Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y: Drug-induced hypoglycemic coma in 102 diabetic patients. (mayocliniclabs.com)
Therapeutic1
  • For example, bacteria that cause disease are agents of the specific diseases they cause, and medicine is a therapeutic agent. (tabers.com)
Antiplatelet agents1
  • The most common pharmacotherapies were cardiovascular agents, followed by antiplatelet agents. (mja.com.au)
Oral agent2
  • In patients for whom diet and exercise do not provide adequate glucose control, therapy with a single oral agent can be tried. (aafp.org)
  • Criteria for initiation of therapy with an oral agent versus insulin are debated among diabetologists, but the decision should be made jointly by the physician and patient to obtain the best results. (aafp.org)
Serum1
  • These agents can reduce the level of serum glycosylated hemoglobin (HbA1c), induce weight loss, and decrease blood pressure [ 8 - 10 ]. (hindawi.com)
Patients1
  • These agents are also used to treat patients with wasting illnesses. (tabers.com)
IMSEAR1
  • IMSEAR at SEARO: Effect of centpiperalone, a new hypoglycemic agent on insulin biosynthesis & release from isolated pancreatic islets of rat. (who.int)
Mesh1
  • Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ucdenver.edu)
Reduce blood glucose levels1
Effect7
  • Further research is needed to determine pramlintide's durability of hypoglycemic effect, as well as effects on patient-reported outcomes, morbidity, mortality, and long-term harms. (annfammed.org)
  • 2. We investigated the insulin-releasing action and hypoglycaemic effect of A-4166 compared to sulphonylureas in vitro and in vivo. (nih.gov)
  • 5. Inf fasted beagle dogs, A-4166 showed a dose-dependent hypoglycaemic effect after oral administration over the range 1 to 10 mg kg-1. (nih.gov)
  • 8. Although the in vitro insulin-releasing effect of A-4166 was similar to that of sulphonylureas, its hypoglycaemic effect was more rapid and shorter-lasting, associated with rapid absorption and clearance. (nih.gov)
  • Short term exposure to mobile phone jammer radiation has a hypoglycemic effect on adult male rats. (greenmedinfo.com)
  • can enhance the hypoglycemic effect of exogenous insulin and strengthen the post-receptor effect of insulin. (chemicalbook.com)
  • Two of them are known as hydroxylated compounds with no hypoglycemic effect and is mainly excreted from the urine and a small amount is excreted by the stool. (chemicalbook.com)
Polycystic ovarian1
  • Ismail KMK, Issa BG, Jones P, Hanna FW, Indusekhar R. Hypoglycaemic agents for pregnant women with polycystic ovarian syndrome. (cochrane.org)
Blood4
  • These episodes of low blood sugar are called hypoglycemic episodes. (medindia.net)
  • Therefore, in the evaluation of the hypoglycemic patient, the possible use of oral hypoglycemic agents as the cause for low blood glucose and elevated plasma insulin must be considered. (mayocliniclabs.com)
  • Proper interpretation requires that the blood specimen be drawn during or close to the time of a hypoglycemic episode. (mayocliniclabs.com)
  • 1 Despite the introduction of new agents to the armamentarium of hypoglycemic agents, efforts for better management of this disease have been disappointing and the control of blood glucose levels remains unsatisfactory. (aafp.org)
Side Effects of Tolectin (tolmetin): Interactions & Warnings
Side Effects of Tolectin (tolmetin): Interactions & Warnings (medicinenet.com)
Onmel (Itraconazole Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
Onmel (Itraconazole Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning (rxlist.com)
Plus it
Plus it (cmaj.ca)
WHO Model List of Essential Medicines - Wikipedia
WHO Model List of Essential Medicines - Wikipedia (en.wikipedia.org)
Oxandrolone Tablets, USP CIII
Oxandrolone Tablets, USP CIII (dailymed.nlm.nih.gov)
Impact of Endocrine Disorders on Skin Disorders | SpringerLink
Impact of Endocrine Disorders on Skin Disorders | SpringerLink (link.springer.com)
Physical Activity/Exercise and Type 2 Diabetes | Diabetes Care
Physical Activity/Exercise and Type 2 Diabetes | Diabetes Care (care.diabetesjournals.org)
Nutropin AQ - FDA prescribing information, side effects and uses
Nutropin AQ - FDA prescribing information, side effects and uses (drugs.com)
Counterpoint: Oral Hypoglyemic Agents Should Be Used to Treat Diabetic Pregnant Women | Diabetes Care
Counterpoint: Oral Hypoglyemic Agents Should Be Used to Treat Diabetic Pregnant Women | Diabetes Care (care.diabetesjournals.org)
DailyMed - GLIPIZIDE tablet
DailyMed - GLIPIZIDE tablet (dailymed.nlm.nih.gov)
Hypoglycemia (Low Blood Sugar) - Causes, Diagnosis, Treatment, Prevention
Hypoglycemia (Low Blood Sugar) - Causes, Diagnosis, Treatment, Prevention (medindia.net)
Dapagliflozin Drug Information - Indications, Dosage, Side Effects and Precautions
Dapagliflozin Drug Information - Indications, Dosage, Side Effects and Precautions (medindia.net)
Elevated Blood Glucose Levels may pose Heart Defect Risk to Infants
Elevated Blood Glucose Levels may pose Heart Defect Risk to Infants (medindia.net)
List of drugs/medicine used for Type 2 Diabetes (Diabetes - Type 2 , Non-Insulin-Dependent Diabetes Mellitus (NIDDM) , Adult...
List of drugs/medicine used for Type 2 Diabetes (Diabetes - Type 2 , Non-Insulin-Dependent Diabetes Mellitus (NIDDM) , Adult... (medindia.net)
High Blood Sugar Impairs Sensory Nerve Regeneration
High Blood Sugar Impairs Sensory Nerve Regeneration (medindia.net)
Free Pharmacology Flashcards about Pharmacology
Free Pharmacology Flashcards about Pharmacology (studystack.com)
Octyl gallate (CHEBI:83631)
Octyl gallate (CHEBI:83631) (ebi.ac.uk)
MedlinePlus: MedlinePlus Web Service
MedlinePlus: MedlinePlus Web Service (medlineplus.gov)
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family Medicine
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus | Annals of Family Medicine (annfammed.org)
Oral hypoglycaemic agents | Springer for Research & Development
Oral hypoglycaemic agents | Springer for Research & Development (rd.springer.com)
Which medications in the drug class Insulin secretion inhibiting agents are used in the treatment of Pediatric Hypoglycemia?
Which medications in the drug class Insulin secretion inhibiting agents are used in the treatment of Pediatric Hypoglycemia? (medscape.com)
Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes - Full Text View - ClinicalTrials.gov
Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes - Full Text View - ClinicalTrials.gov (clinicaltrials.gov)